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Parkinson's diseaseThere has been increasing evidence pointing to the mitochondrial respiratory chain (MRC) as a novel and
important target for the actions of 17β-estradiol (E2) and estrogen receptors (ER) in a number of cell types
and tissues that have high demands for mitochondrial energy metabolism. This novel E2-mediated
mitochondrial pathway involves the cooperation of both nuclear and mitochondrial ERα and ERβ and their
co-activators on the coordinate regulation of both nuclear DNA- and mitochondrial DNA-encoded genes for
MRC proteins. In this paper, we have: 1) comprehensively reviewed studies that reveal a novel role of
estrogens and ERs in the regulation of MRC biogenesis; 2) discussed their physiological, pathological and
pharmacological implications in the control of cell proliferation and apoptosis in relation to estrogen-
mediated carcinogenesis, anti-cancer drug resistance in human breast cancer cells, neuroprotection for
Alzheimer's disease and Parkinson's disease in brain, cardiovascular protection in human heart and their
beneﬁcial effects in lens physiology related to cataract in the eye; and 3) pointed out new research directions
to address the key questions in this important and newly emerging area. We also suggest a novel conceptual
approach that will contribute to innovative regimens for the prevention or treatment of a wide variety of
medical complications based on E2/ER-mediated MRC biogenesis pathway.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionEstrogens, notably 17β-estradiol (E2), have a wide variety of
physiological and pathological effects on a number of cell types and
organs, including primary and secondary reproductive, cardiovascular,
central nerve, immune, bone, gastrointestinal, and respiratory systems
as well as oral and lens epithelial cells. The classical genomic
mechanisms underlying the regulation of nuclear gene transcription
by estrogens via the nuclear estrogen receptors alpha and beta (ERα and
ERβ) have been well-established (for review see [1,2]). Recently, great
interest has also been drawn to the non-genomic pathways involving
plasmamembrane-associated ERs that activate a numberof intracellular
protein kinase-mediated phosphorylation signaling cascades and the
subsequent physiological activities (for review see [3–8]). In recent
years, there has been increasing evidence pointing to themitochondrial
respiratory chain (MRC) as a novel and important target for the actions
of E2 and ERs in a number of cell types and tissues that have high
demand for mitochondrial energy metabolism for their biologicall rights reserved.activities. This novel E2-mediated mitochondrial pathway involves the
cooperation of the nuclear ERα and ERβ with mitochondrial localized
ERs and their co-activators on the coordinate regulation of both nuclear
DNA (nDNA)-encoded genes and mitochondrial DNA (mtDNA)-
encoded genes for MRC proteins. In this paper, we have: 1) reviewed
recent studies that reveal a novel role of estrogens and ERs in the
regulation ofMRC biogenesis; 2) discussed their potential physiological,
pathological and pharmacological implications in the control of cell
proliferation and apoptosis in relation to estrogen-mediated carcino-
genesis in human breast cancer cells, cardiovascular protection in heart,
neuroprotection for Alzheimer's disease and Parkinson's disease in brain
and their beneﬁcial effects in lens physiology related to cataract in the
eye; and 3) pointed out new research directions to address the key
questions in this important and newly emerging area.
2. MRC structure, functions and biogenesis
2.1. MRC structure and functions
MRC (also called electron transport chain) (Fig. 1) is one of the
most important structural and functional parts of mitochondria. MRC
Fig. 1. MRC, H+-ATP synthase and ANT. A schematic picture showing MRC complexes, H+-ATPase, and ANT. MRC: Mitochondrial respiratory chain; ANT: Adenosine Nucleotide
Translocase.
1541J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1540–1570consists of a series of metalloproteins bound to the mitochondrial
inner membrane (also named cristea). There are four large protein
complexes (designated complex I to complex IV) that are associated
with mitochondrial electron transport. These complexes cooperate in
electron transfer and proton pumping across the inner mitochondrial
membrane. Electron transfer between these complexes is accom-
plished by the mobile coenzymes ubiquinone (CoQ) in the lipid
membrane, from complexes I and II to complex III and cytochrome c in
the inter-membrane space, from complex III to complex IV. The
mitochondrial F0–F1 ATP synthase couples the proton gradient across
the mitochondrial inner membrane to the synthesis of ATP from
ADP+Pi. The best-known function of MRC is its ability to generate theFig. 2. Human mitochondrial genome. The relative locations of genes encoding 13 MRC
proteins for complex I (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6); complex III (cytb);
complex V (COX I, COX II and COX III) and H-ATP synthase (ATP6/8), two rRNAs (12 S
rRNA and 16 S rRNA) and 22 tRNAs for speciﬁc amino acids indicated by the letters are
shown. F: Phe; V: Val; L: Leu; I: Ile; Q: Gln; M:Met;W: Trp; A: Ala; N: Asn; C: Cys; Y: Tyr;
S1: Ser, D: Asp; K: Lys; G: Gly; R: Arg; H: His; S2: Ser-2; L2: Leu-2; E: Glu; P: Pro; T: Thr;
D-loop: Displace loop.vast majority (more than 90%) of cellular energy in the form of ATP,
which is essential to drive and maintain the majority of the
physiological activities. In addition, MRC also generates a large
quantity of reactive oxygen species (ROS) as by-product, which is
the major source of cellular ROS. ROS play an important role in redox
regulation of gene expression, the control of cell proliferation and
apoptosis, as well as serving as the second messenger involved in the
regulation of a number of physiological and pathological activities
(see below). The ROS also have the potential for causing oxidative
damage to DNA and other critical molecules within the mitochondria.
Together, the MRC-generated ATP and ROS play crucial roles in
regulating the large majority of physiological and pathological
activities of the cells.
Human/mammalian mitochondria contain their own genetic
system, which undergoes a unique mode of cytoplasmic inheritance.
Each organelle has multiple copies of a covalently closed circular,
16.6 Kb DNA genome (mitochondrial DNA, mtDNA), which encodes
mRNAs for 13 essential subunits of MRC, 2 rRNAs (12 S and 16 S), and
22 tRNAs that are needed for mitochondrial protein synthesis (9)
(Fig. 2). The majority of MRC proteins and all of the other protein
factors that are involved in replication–transcription–translation of
mtDNA, assembly of MRC complexes, heme biosynthesis, mitochon-
drial protein import machinery and other mitochondrial functions
(see Section 2 MRC structure, functions and biogenesis and Section 3
Regulation of mtDNA-encoded MRC proteins by E2 and ERs) are
encoded by nuclear genes. Coordination of the expression of the
nDNA- and mtDNA-encoded genes is thus essential for maintaining
normal mitochondrial functions and responses to pathological and
environmental factors. The structural components, functions and
assembly/biogenesis of the individual MRC complexes are brieﬂy
described as follows.
2.2. MRC complexes, ATP synthase and MRC assembly proteins
2.2.1. Complex I—NADH–ubiquinone oxidoreductase
Complex I (NADH–ubiquinone oxidoreductase, EC 1.6.5.3), the
largest among the MRC complexes, has two domains that form a
L-shape: one hydrophobic domain lies within and is oriented parallel
to the membrane, while a hydrophilic arm extends into the mito-
chondrial matrix. This complex transports two electrons from
tricarboxyl acid (TCA) cycle-derived NADH in the mitochondrial
1542 J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1540–1570matrix to quinone (Q) within the membrane, via ﬂavin mononucleo-
tide (FMN) and a series of seven iron–sulphur clusters. FMN can break
up the simultaneous transfer of two electrons fromNADH alongwith a
proton, transferring H+ into two separate one-electron steps, as
required for electron transfer through the iron–sulphur clusters.
Complex I is also a major site of superoxide (O−•) generation as a by-
product due to the direct reaction of electrons that leak from this site
with dioxygen (Fig. 1).
Complex I consists of 46 protein subunits with seven subunits
being encoded by mtDNA and the remaining 39 subunits being
encoded by nuclear DNA (nDNA) (Table 1A). The mtDNA-encoded
subunits play the major catalytic role of the enzyme. The majority of
the nDNA-encoded subunits provide the regulatory functions. They
are sub-classed into ﬂavoprotein (FP), iron–sulfur protein (IP), and
hydrophobic protein (HP) subclasses. The FP contains three subunits
with molecular masses of 51, 24, and 9 kDa, respectively. The 51-kDa
subunit contains FMN and a tetranuclear iron–sulfur cluster and is the
principal site of entry for electrons donated by NADH into the MRC.
The 24-kDa subunit contains a binuclear iron–sulfur cluster [9]. IP
subclass contains seven subunits, designated NDUFS1 to NDUFS7, with
molecular masses of 75, 49, 30,18,15, 13, and 11 kDa, respectively [10].
This subclass is important because it contains important prosthetic
groups highly conserved among species. It is noted that the NDUFS2
contains a highly conserved protein kinase C phosphorylation site and
the NDUFS3 subunit contains a highly conserved casein kinase II
phosphorylation site [10]. This makes them strong candidates to be
regulated by phosphorylation/dephosphorylation, an important reg-
ulatory mode that can control their activity [11]. FP and IP make
contact through the 51- and the 75-kDa subunits. The hydrophobic
protein (HP) subclass, which includes more than thirty subunits, is
largely membrane-intercalated and contains two iron–sulfur clusters
apparently in a 23-kDa subunit and possibly another in a 20-kDa
subunit [9]. Stoichiometrically, per mole of complex I, there are 2 mol
of the 15-kDa subunit and 1 mol each of the FP and the four largest IP
subunits [9].
The biogenesis of intact complex I requires the correct assembly of
both mtDNA- and nDNA-encoded subunits. The mtDNA-encoded
subunits ﬁrst assemble into intermediate complexes and require
signiﬁcant chase times for their integration into the holoenzyme. InTable 1A
Properties of mtDNA- and nDNA-encoded complex I subunits and complex I assembly prot
Complex I subunits Properties
NRF-1 and NRF-2
mtDNA-encoded ND1 via Tfam
ND2 via Tfam
ND3 via Tfam
ND4 via Tfam
ND4L via Tfam
ND5 via Tfam
ND6 via Tfam
nDNA-encoded FP NDUFV1 NRF-2
NDUFV2
NDUFV3
IP NDUFS1
NDUFS2
NDUFS3
NDUFS4
NDUFS5
NDUFS6
NDUFS7
NDUFS8 NRF-1
NDUFA8
HP 31 subunits
Nuclear-encoded assembly proteins CIA30
NDUFAF1
C20orf7
C6orf66contrast, a set of newly imported nDNA-encoded subunits integrates
with pre-existing complex I subunits to form intermediates and/or the
fully assembled holoenzyme. One of the intermediate complexes
represents a subassembly associated with the chaperone protein
B17.2L. Recent studies (for review see [12]) have pointed to a
mechanism of complex I biogenesis involving two complementary
processes: (i) synthesis of mtDNA-encoded subunits to seed de novo
assembly and (ii) exchange of pre-existing subunits with newly
imported ones to maintain complex I homeostasis. Subunit exchange
may also act as an efﬁcient mechanism to prevent the accumulation of
oxidatively damaged subunits that would otherwise be detrimental to
mitochondrial oxidative phosphorylation and have the potential to
cause disease.
Several proteins including mtDNA-encoded ND6 [13] and the
nDNA-encoded CIA30 (complex I intermediate associated protein)
[14], NDUFAF1 [15], C20orf7 [16] and C6ORF66 [17] have been known
to play essential roles in complex I assembly. CIA30 associates with the
newly translated mtDNA-encoded complex I subunits at early stages
in their assembly before dissociation at a later stage. CIA30-deﬁciency,
which causes reduced levels and activity of complex I, was detected in
a patient with cardioencephalomyopathy. Genetic analysis has
revealed that the patient had mutations in both alleles of the NDU-
FAF1 gene that encodes CIA30. Complex I assembly in patient's cells is
defective with subunits being degraded at early stages of develop-
ment. Complementing the deﬁciency in patient ﬁbroblasts with
normal CIA30 restores steady-state complex I levels [14]. C20orf7
peripherally associates with the matrix face of the mitochondrial
innermembrane. Silence of its expressionwith small interference RNA
(siRNA) decreases complex I activity. Furthermore, mutation of
C20orf7 disrupts complex I assembly and causes lethal neonatal
mitochondrial disease[16]. NDUFAF1 has been demonstrated to be an
important protein for the assembly and stability of complex I.
NDUFAF1 is associated to two intermediate complexes of 600 and
700 kDa in size. The 700 kDa complex appears to represent a key step
in the complex I assembly process. The relative distribution of these
two complexes is altered in two complex I-deﬁcient patients. Knock
down of NDUFAF1 expressionwith siRNA led to a reduced amount and
activity of complex I [15]. Homozygosity mapping in ﬁve patients from
a consanguineous family presented with infantile mitochondrialeins.
binding sites Other factor binding sites Regulated by E2/ERs References
TFBIM and TFBIIM + [48,79]
TFBIM and TFBIIM
TFBIM and TFBIIM
TFBIM and TFBIIM
TFBIM and TFBIIM
TFBIM and TFBIIM
TFBIM and TFBIIM
Sp1 and YY1 [143]
+ [116]
Sp1 and YY1 + [116,142]
Table 1C
Properties of mtDNA amd nDNA-encoded complex III subunits and assembly proteins.
Complex III subunits Properties
NRF-1/NRF-2
binding sites
Other factor
binding sites
Regulated
by E2/ERs
References
mtDNA-encoded Cytb via Tfam TFBIM and
TFBIIM
+ [48]
nDNA-encoded QCR6 N/A N/A +
QCR8 N/A N/A
QCR9 N/A N/A [116]
QCR10 N/A N/A
nDNA-encoded
assembly proteins
QCR7 N/A N/A
BCS1L N/A N/A
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conserved residue of the C6ORF66 gene, which encodes a 20 kDa
mitochondrial protein [17]. The samemutation has also been detected
in a patient who had antenatal cardiomyopathy. In muscle of two
patients, the levels of the C6ORF66 protein and the fully assembled
complex I were markedly reduced. Transfection of the patient's
ﬁbroblasts with wild-type C6ORF66 cDNA restored complex I activity.
These data suggest that C6ORF66 is an assembly factor of complex I.
More importantly, the C6ORF66 gene product was found to promote
invasiveness of breast cancer cells [17].
2.2.2. Complex II—succinate dehydrogenase
Complex II (succinate dehydrogenase, EC 1.3.5.1) oxidizes succi-
nate to fumarate and reduces quinone (Q) to QH2 within the
membrane. The electron transfer from FDAH2 proceeds initially via
an FAD cofactor, and then through a series of three iron–sulphur
clusters. The ﬁrst is a [2Fe2S] cluster where one of the Fe atoms is
bound by aspartate oxygen. The second and third ones are the [4Fe4S]
and [3Fe4S] clusters. All these groups are in the hydrophilic protein
chains external to the membrane. Finally, electrons pass through the
home iron of cytochrome b560 (within the hydrophobic protein inside
the membrane), and then outside the protein to ubiquinone, which
binds near the heme group.
Complex II contains four nDNA-encoded subunits but no mtDNA-
encoded subunits: the ﬂavoprotein (FP) and iron–sulfur protein (IP)
of the dehydrogenase, and two integral membrane proteins referred
to as C (II-3) and D (II-4). Their respective genes in mammals are
SDHA, SDHB, SDHC and SDHD [18] (Table 1B). Mutations in any of
these may disrupt complex II enzymatic activity. In fact, defects in
SDHA produce a bioenergetic deﬁciency while defects in SDHB, SDHC,
or SDHD induce tumor formation, suggesting that complex II has
tumor suppressor functions. It has been demonstrated that loss of the
SDHB, but not the SDHA, subunit triggers ROS-dependent hypoxia
inducible factor activation and tumorigenesis [19]. SDHB, SDHC, and
SDHD germline mutations are prevalently detected in patients with
head and neck paragangliomas [20–22]. These observations suggest
that the dysfunction and loss of these genes due to mutations can
have an important role in the malignant transformation of the
paragangliomas.
2.2.3. Complex III—cytochrome bc1 complex
Complex III (ubiquinol cytochrome c reductase, EC 1.10.2.2)
catalyzes electron transfer from succinate via FDAH2− and NADH-
linked dehydrogenases to cytochrome c, a mobile electron carrier
located outside the mitochondrial membrane, shuttling one electron
at a time from complex III to complex IV.
Complex III can be divided into two halves. Each half has a binding
site for the lipid-mobile carrier ubiquinol/ubiquinone (QH2/Q). Quinol
oxidation takes place near the inter-membrane space, while quinone
reduction takes place near the matrix side of the membrane. Half the
electrons delivered at Qo pass through the complex to Qi. Because the
redox of Q/QH2 also involves the transfer of protons, this process
results in the release of protons into the inter-membrane space and
the uptake of protons from the cell matrix. In effect, H+ has been
transported from one side of the membrane to the other, even thoughTable 1B
Properties of nDNA-encoded complex II subunits.
Genes Properties
NRF-1 and NRF-2
binding sites
Other
factors
Regulated
by E2/ERs
References
nDNA-encoded SDHA NRF-1 NA + [122]
SDHB NRF-1; NRF-2 N/A [116,120]
SDHC NRF-1; NRF-2 N/A [18]
SDHD NRF-1; NRF-2 N/A [121]
Cyt C NRF-1; NRF-2 + [67,118]it is not actually the same proton coming and going. The other half is
delivered to another inter-membrane-mobile carrier, cytochrome c,
which contains a heme groupwith two axial ligands, one hisN and one
metS, giving octahedral coordination to the iron atom. The two iron
oxidation states are Fe(III) d5 and Fe(II) d6, both low spin. The transfer
of a non-bonding t2g electron doesn't dramatically affect the
coordination geometry of the iron atom, making for kinetically facile
electron transfer. There are two pathways for electrons to pass
through complex III from ubiquinol at Qo. One is via two heme iron
centers, cytochromes b562 (or bL, with a lower potential) and b566 (or
bH, with a higher potential), and then to ubiquinone at Qi. The other is
via a Rieske iron–sulphur cluster to cytochrome c1, and then to
cytochrome c. Complex III is another site for generation of superoxide
within MRC (see Fig. 1).
Complex III is made up of 11 subunits, of which all but one
(cytochrome b) (cytb), are encoded by nDNA (Table 1C). The
biogenesis of the yeast MRC complex III has been described (for
review see [23]). Several studies have indicated that the mtDNA-
encoded Cytb plays an important role not only in assembly of complex
III but also in the maintenance of the complex I stability. Mutations in
the cytb gene are associated either with only a complex III deﬁciency
or with a combined complex I and III deﬁciency. In the processes of the
assembly of the entire MRC, the complexes I and III form a stable core
respirasome to which complex IV binds. The formation of respira-
somes is essential for the assembly and stability of complex I. The
dependence of complex I stability on the Cytb-mediated assembly of
complex III has been demonstrated by a study using mouse and
human cultured cell models harboring cytb mutations with a
combined complex I and complex III defects. In both, complex III
assembly was impeded and causes a severe reduction in the amount of
complex I, not observed when complex III activity was pharmacolo-
gically inhibited. Metabolic labeling in mouse cells revealed that
complex I was assembled, but its stability was severely hampered.
Conversely, complex III stability was not inﬂuenced by the absence of
complex I. This structural dependence among complexes I and III was
conﬁrmed in a muscle biopsy of a patient harboring a nonsense cytb
mutation [24,25]. In addition to Cytb, a nuclear gene named BCS1L,
which encodes a member of the AAA family of ATPases, is required for
the assembly of complex III and for the expression of functional Rieske
iron–sulfur protein. Mutations in this gene cause disruption of
complex III assembly, associated with reduced activity of the MRC
and increased ROS production. A number of functional mutations in
BCS1L have been reported in patients with tubulopathy, encephalo-
pathy, liver failure and the Bjrnstad syndrome [26,27]. More recently,
pathogenic mutations in the 5′ untranslated region of BCS1L mRNA
have been identiﬁed, which were associated with decreased BCS1L
mRNA and protein levels, and a complex III assembly impairment [28].
2.2.4. Complex IV—cytochrome c oxidase (COX)
Complex IV [cytochrome c oxidase (COX), EC 1.9.3.1], the major
component of the MRC complex localized within the mitochondrial
inner membrane, acts as the terminus of mitochondrial electron
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of four protons across the mitochondrial inner membrane, driving the
synthesis of ATP via mitochondrial F0–F1 ATP synthase (Section 2.2.5
Complex V—mitochondrial F0–F1 ATP synthase). In each half of COX,
there are three metal sites involved in electron transfer: bimetallic
CuA, monometallic cytochrome a, and bimetallic cytochrome a3/CuB.
In addition, there are non-redox Mg2+ and Zn2+ ions, which, along
with the CuB/cyt a3 site, may be involved in the proton-pumping
mechanism. Cytochrome c initiates electron ﬂow through the enzyme
by delivering one electron at a time to CuA, which sits just outside the
membrane. Electrons ﬂow from CuA through cyt a to the a3/CuB site,
which is where O2 is bound and reduced to water. With four one-
electron redox centers (CuA, cyt a, CuB, and cyt a3), the enzyme can
hold the four electrons needed for the complete reduction of a single
O2 molecule.
Complex IV consists of thirteen subunits (Table 1D). Of which, the
largest subunits, COXI, COXII, and COXIII, are encoded by the mtDNA
and synthesized within the mitochondria. They represent the
catalytic core of the enzyme; the rest of the smaller subunits are
encoded by nDNA and imported into mitochondria following their
synthesis in the cytosol. The nDNA-encoded subunits are implicated
in the regulatory functions. Thus, its biosynthesis involves a
coordinate interplay between nuclear and mitochondrial genomes.
The subunits IV, Va, Vb, VIb, VIc, VIIb, VIIc, and VIII(L) are ubiquitously
expressed in all the tissues, although the mRNA levels for the
individual subunits vary in different tissues. Several nDNA-coded
subunits are expressed in a tissue- and development-speciﬁc manner.
For example, the subunits VIa (H), VIIa (H), and VIII (H) are exclusive
to heart and skeletal muscle. COX biogenesis includes a variety of
steps starting from translation to the formation of the mature
complex. Each step involves a set of speciﬁc factors that assists
translation of subunits, their translocation across membranes, the
insertion of essential cofactors, assembly and ﬁnal maturation of the
enzyme. The organization and biogenesis of COX have been described
(for details see [29,30]).
The COX IV assembly/biogenesis relies on a number of proteins,
including SCO1, SCO2, COX11, COX15, Surf1p, COX17 and SURF1 (Table
1D), which are essential for the correct assembly and stability of this
complex. SCO1, SCO2 and COX17 are also responsible for delivery of
copper ions to the mitochondrion and for insertion of these ions into
the enzyme and maintenance of cell copper homeostasis [31–33].Table 1D
Properties of mtDNA amd nDNA-encoded complex IV subunits and complex IV assembly pr
Complex IV subunits Properties
NRF-1 and NRF-2 binding sites
mtDNA-encoded COXI via Tfam
COXII via Tfam
COXIII via Tfam
nDNA-encoded COXIV NRF-1; NRF-2
COXVa NRF-1; NRF-2
COXVb NRF-1; NRF-2
COXVIb NRF-1; NRF-2
COXVIc NRF-1; NRF-2
COXVIIb NRF-1; NRF-2
COXVIIc NRF-1; NRF-2
COXVIII NRF-1; NRF-2
COXVIa (L) NRF-1; NRF-2
COXVIa (H)
COXVIIa (L) NRF-1; NRF-2
COXIIa (H)
COXVIII (H/L)
nDNA-encoded assembly proteins COX17p NRF-1; NRF-2
SCO1
SCO2
SURF1
COX11
COX15Mutations in SCO2 have been reported in infants with early onset of
fatal cardioencephalomyopathy andwho have a severe COX deﬁciency
in striated muscle [33–35]. More interestingly, SC02 has been known
to couple with p53 within mitochondria in modulating the balance
between the utilization of MRC and glycolytic pathways [36].
Maturation of the heme a (3)-Cu(B) center is a step that limits the
association of subunits I and II in the COX assembly. Surf1p plays a role
in facilitating the insertion of heme into the active site of COX.
Numerous mutations in human Surf1p lead to severe mitochondrial
disease with defective complex IV functions [37]. Surf1 appears to be
involved in an early step of heme insertion into subunit I [38]. In
humans, the loss of Surf1 function due to mutations is associated with
Leigh syndrome, a fatal neurodegenerative disorder which is highly
prevalent in Poland [39].
2.2.5. Complex V—mitochondrial F0–F1 ATP synthase
Complex V (themitochondrial F0–F1 ATP synthase) is a membrane
protein complex, consisting of catalytic sector, F1; the membrane
sector, F0, and a long stalk that connects F1 to F0 (Fig. 1). F0–F1 ATP
synthase couples the proton gradient across the mitochondrial inner
membrane to the synthesis of ATP from ADP+Pi. The complex is
composed of essential subunits for its motor functions and super-
numerary subunits. Two subunits of ATP synthase, subunits 6 and 8
(ATP6/8), are encoded by mtDNA and the remaining subunits are
encoded by nDNA (Table 1E). The well characterized subunits of the
bovine ATP synthase complex are the subunits alpha (α), beta (β),
gamma (γ), delta (δ), and epsilon (ɛ) of F1; the ATPase inhibitor
protein; and subunits a, b, c, and d, OSCP (oligomycin sensitivity-
conferring protein), F6, and A6L are present in F0, and the 45-A-long
stalk. Bovine ATP synthase preparations also contain three small
polypeptides, designated e, f, and g, with respective molecular masses
of 8.2, 10. 2 and 11.3 kDa, respectively. It has been shown that (i) e, f,
and g could be immunoprecipitated with anti-OSCP from a fraction of
bovine submitochondrial particles enriched in oligomycin-sensitive
ATPase;(ii) the NH2 termini of subunits f and g are exposed on the
matrix side of themitochondrial innermembrane and can be curtailed
by proteolysis; (iii) the COOH termini of all three polypeptides are
exposed on the cytosolic side of the inner membrane; and (iv) f cross-
links to A6L and to g, and e cross-links to g and appears to form an e–e
dimer. Thus, the bovine ATP synthase complex appears to have 16
subunits [10].oteins.
Other factor binding sites Regulated by E2/ERs References
TFB1M and TFBIIM + [48,51,53,55,67,79]
TFB1M and TFBIIM + [48,51,53,55]
TFB1M and TFBIIM + [48,51,53,55]
Sp1 + [67,76,79,130,135,136]
+ [115,130,135,136]
Sp1; Ets; NF-E1 + [126,127,130,135,136]
+ [130,135,136]
+ [130,135,136]
+ [130,135,136]
+ [130,135,136]
+ [128,133,134]
Sp1; YY-1; Est [124]
MEF2A
Sp1
MEF2A + [116,137]
Sp1 [128]
Table 1E
Properties of mtDNA amd nDNA-encoded ATP synthase subunits and assembly proteins.
F0–F1 ATP synthase subunits Properties
NRF-1/NRF-2
binding sites
Other factors
binding sites
Regulated
by E2/ERs
References
mtDNA-
encoded
ATP6 via Tfam TFBIM and
TFBIIM
+ [48]
ATP8 via Tfam TFBIM and
TFBIIM
+ [48]
nDNA-
encoded
F0 Inhibitor
protein
a
b
c
d + [116]
e + [116]
f + [115]
g + [115]
OSCP
J + [114]
F6
A6L
F1 Alpha (α) ATPF1; YY-1
Beta (β) + [116]
Gamma (γ) NRF-1 [142]
Delta (δ)
Epsilon (ɛ) + [114]
Stalk 45-A
nDNA-
encoded
assembly
proteins
Oxal
ATP12
TMEM70
1545J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1540–1570The assembly of mitochondrial F0–F1 ATP synthase is a compli-
cated process, which is not fully understood. However, several
proteins including Oxa1, ATP12, subunit ɛ and TMEM70 are involved
in the assembly and biogenesis of this complex. The Oxa1 protein is
involved in assembly of the COX complex by facilitating the co-
translational membrane insertion of mtDNA-encoded COX subunits. It
has been demonstrated [40] that Oxa1 also directly supports the
assembly of the inner membrane embedded F0-sector of the ATP
synthase via its physical interaction with the newly synthesized
mtDNA-encoded ATP8 protein. In the absence of Oxa1, ATP8 is
observed to assemble into an oligomeric complex containing F1-
subunits, but its further assembly with subunit 6 (ATP6) of the F0-
sector is perturbed. By directly interacting with newly synthesized
ATP8 in a posttranslational manner, Oxa1 is required to maintain the
assembly competence of the ATP8-F1-subcomplex for its association
with ATP6. Subunit ATP12 is also involved in assembly for F0–F1 ATP
synthase. A mutation in the ATP12 gene has been identiﬁed in one
patient, which is believed to be the cause of the impaired ATP synthase
activity [41]. Bisetto et al. [42] have determined that integral inner
membrane subunit ɛ is essential for self-association of F0–F1 ATP
synthase. Whole-genome homozygosis mapping, gene expression
analysis and DNA sequencing in individuals with an isolated
mitochondrial ATP synthase deﬁciency led to identiﬁcation of
disease-causing mutations in TMEM70. Complementation of the cell
lines derived from these individuals with wild-type TMEM70 restored
biogenesis and metabolic function of the enzyme complex. These
results indicate that TMEM70 is involved in mitochondrial ATP
synthase biogenesis [43].
3. Regulation of mtDNA-encoded MRC proteins by E2 and ERs
Mitochondria integrate a large number of signal transduction
pathways for a wide variety of biologically active molecules. There is
increasing evidence that mtDNA is one of the major targets for the
direct actions of steroid and thyroid hormones and their respective
receptors (for reviews see [44–47]). The regulation of mtDNA-
encoded MRC protein synthesis by E2 and ERs is described as follows.3.1. Localization of ERβ and ERα in mitochondria of target cells/tissues
In addition to their presence in nuclei and plasma membrane, ERα
and ERβ are also localized in mitochondria of a number of cell types
and tissues. While several earlier studies have provided several clues
suggesting the association of ERs with non-nuclear/cytoplasmic
compartments in target tissues (for review see [46]), deﬁnitive
demonstration for the presence of ERα and ERβ in mitochondria in
target cells comes from more recent studies. The studies examining
the effects of 17β-ethinyl estradiol plus and minus ER antagonist
ICI182780 on MRC gene expression and MRC-mediated superoxide
generation in human liver cancer HepG2 cells provided the ﬁrst line of
evidence suggesting the presence of ERs in their mitochondria [48,49].
Monje and Boland reported the ﬁrst direct detection of ERβ in the
mitochondria in rabbit uterus and ovary [50]. Using subcellular
fractionation/Western blot, immunochemical localization with con-
focal ﬂuorescent microscopy and immunogold microscopy, Chen et al.
[51–53] demonstrated that a substantial fraction (approximately 20%)
of total cellular ERβ are localized within the mitochondrial matrix of
human breast cancer MCF-7 and that E2 enhanced the import of ERβ
into MCF-7 cell mitochondria in a time- and dose-dependent manner.
Pedram et al. [54] independently conﬁrmed the presence of functional
ERβ in MCF-7 and endothelial cells. Chen et al. [55] observed that ERβ
is predominantly localized in mitochondria of normal, immortalized
human breast epithelial cells (MCF-10F) and the E2-induced trans-
formed subline of MCF-10F cells (trMCF). More importantly, they
demonstrated that silence of ERβ expression with ERβ-speciﬁc siRNA
markedly diminished both nuclear andmitochondrial ERβ in MCF-10F
and MCF-7 cells. In addition, they observed a progressive shift of ERβ
from its predominant localization in mitochondria in MCF-10F and
trMCF to the nuclei of the more invasive and tumorigenetic MCF-10F
sub-lines [55]. The mitochondrial localization of ERβ has been
extended to a number of cell type and tissues. Yang et al. [56]
demonstrated the mitochondrial localization of ERβ in primary
neurons, primary cardiomyocytes, murine hippocampus cell lines
and human heart cells. Moreover, they veriﬁed, using a proteomic
approach, that a protein with a molecular weight between 50 to
60 kDa within mitochondria of human heart cells was ERβ.
Furthermore, ERβ has been detected in mitochondria of human lens
epithelial cells [57–59], human liver cancer HepG2 cells [53,60],
osteosarcoma SaOS-2 [60,61], sperm [62], periodontal ligament cells
[63], and rat brain rostral ventrolateral medulla and the hippocampal
CA1 region where silver grains indicative of 125I-estradiol binding are
localized [64,65].
It should be noted that the wild-type human ERβ (designated
ERβ1) coexists with several isoforms (designated ERβ2 to ERβ5) in a
wide range of tissues. These isoforms are generated via alternative
splicing of exons encoding the carboxyl terminus. Using antibodies
speciﬁc for ERβ1, ERβ2 and ERβ5, Cammarata et al. [58] observed that
ERβ-1 immunostaining was prominently present in the mitochondria
along with weaker staining in the nucleus of normal cultures of
human lens epithelial cells (nHLE), virally transformed HLE-B3 and
MCF-7 cells, as determined by co-localization with Mitotrack-633.
However, ERβ2 staining was distributed throughout the cytosol and
was associated with the nucleus of these cells. ERβ5 staining was
diffuse in the cytosol and also associated with their nuclei. The
differential subcellular distribution of ERβ1 to the mitochondria and
ERβ2 to the nucleus suggests a new aspect of regulation and function
of the ER signaling systems. Indeed, ERβ1 has been shown to play an
important role in mitochondrial cytoprotection from oxidative stress
in cultured normal male and female human lens epithelial cells [59]
(see Section 7.5. Implications in beneﬁcial effects of estrogens/ERs on
lens physiology for more details).
The presence of ERβ1 but not of ERβ2 and ERβ5 in mitochondria
of many types of cells and tissues indicates that, like other mitochond-
rially-localized proteins, ERβ1 is imported into mitochondria via
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requires the mitochondrial targeting polypeptide signal (mTPs) and
information encoded within the carboxyl terminus of ERβ1. Indeed, a
putative mTPs has been identiﬁed within the internal amino acid
sequence of humanERβ1 [14,51]. It is likely that ERβ is imported into the
mitochondria of target cells, through tethering to cytosolic chaperone
protein and/or through direct interaction with mitochondrial import
proteins [66]. The mechanisms underlying the mitochondrial import of
ERβ deserves further investigation.
While ERα is mainly present in the nucleus, several studies have
demonstrated its presence in mitochondria of several types of cells,
including cerebral blood vessels obtained from ovariectomized (Ovx)
female rats [67], MCF-7 cells [51,54,68], HepG2 cells [53,60], and 2C12
murine skeletal muscle cell line [69].
The presence of ERα and ERβ in mitochondria of breast, heart,
brain, bone, eyes, sperm, and periodontal ligament tissues, which have
high demand on energy supply from mitochondria for their proper
functions, indicates that mitochondrial ERα and ERβ may have
important roles in the regulation of mitochondrial energy metabolism
in these systems (see Section 7 Physiological and pathological
implications).
3.2. Induction of mtDNA transcription by E2 and ERs
E2 has been known to up-regulate the transcript levels of several
mtDNA genes, which encode MRC complex proteins, and to have
direct and indirect effects on MRC activity [48,51,53,70–72]. The
previous studies on the effects of estrogens on the transcript levels of
mtDNA genes encoding MRC proteins in a number of cell types and
tissues have been reviewed ([46,73] and references therein) and
summarized [74]. A number of recent studies have provided strong
additional support for an important role of E2 in the regulation of the
expression of mtDNA-encoded MRC proteins.
It was reported [67] that treatment of Ovx female rats in vivo with
E2 increased the levels of a number of speciﬁc proteins in
cerebrovascular cell mitochondria, including mtDNA-encoded COX1,
the nDNA-encoded cytochrome c and COX IV of complex IV, ERα and
manganese superoxide dismutase (MnSOD), associated with
increased complex IV activity. Irwin et al. [75] investigated the effects
of progesterone (P) and E2 on mitochondrial functions. They treated
Ovx rats with P, E2, or E2+P and then isolated whole-brain
mitochondria for functional assessment and observed that brain
mitochondria from E2-treated rats exhibited increased expression and
activity of complex IV coupled to MRC functions, and that this
increased MRC activity was coupled with a decreased rate of reactive
oxygen leakage and reduced lipid peroxidation, representing a
systematic enhancement of brain mitochondrial efﬁciency. Hsieh et
al. [76] treated male rats underwent trauma–hemorrhage (T–H) with
either ERα selective agonist propylpyrazole triol (PPT) or ERβ
selective agonist diarylpropionitrile (DPN) or E2 or vehicle and
another group of rats with complex IV inhibitor sodium cyanide (SCN)
±DPN. Their results indicated that 24 h after T–H, cardiac functions
were depressed in the vehicle-treated but were normal in DPN-
treated rats. Either E2 or DPN treatment after T–H normalized cardiac
mitochondrial ERβ expression and increased mitochondrial ERβ DNA-
binding activity, accompanied by an increase in complex IV gene
expressions and activity. Moreover, inhibition of complex IV in DPN-
treated T–H rats by SCN abolished the DPN-mediated cardioprotec-
tion, ATP production, mitochondrial cytochrome c release, caspase-3
cleavage, and apoptosis. These results indicate that E2 and ERβ-
mediated cardioprotection following T–H appears to be mediated via
mitochondrial ERβ-dependent complex IV activity and inhibition of
mitochondrial apoptotic signaling pathways. Human periodontal
ligament (PDL) cells express mainly ERβ protein. Jonsson et al. [63]
demonstrated ERβ in mitochondria of PDL cells, in which E2 induced
attenuation of the expression of COXI of complex IV, an effect that wasblocked by ER antagonist, ICI182780. Chen et al. [55] reported that
treatment of immortalized human breast epithelial cells that are
negative to ERα but contain ERβ in their mitochondria with E2 and
DPN for 24 h signiﬁcantly stimulated the expression of subunits COX I
and COX II of complex IV, and ND1 subunit of complex I and that knock
down of ERβ expression with siRNA diminished the mitochondrial
expression of ERβ in these cells and blocked E2-induced expression of
COXII protein. These results demonstrated that the mitochondrial ERβ
in MCF-10F cells is directly involved in E2-induced expression of
mtDNA-encoded MRC proteins. Consistent with these observations,
Nilson et al. [77] reported increased mRNA and protein levels of COXI,
COXII and COXIII in mitochondria of rat brain neurons and commitant
increase in COX activity.
3.3. Activation of nuclear respiratory factors (NRFs) and mitochondrial
transcription factor A (Tfam) by E2/ERs
3.3.1. Activation of NRFs by E2 and ERsα
While the molecular mechanisms underlying the above-described
E2/ER-mediated effects on expression of mtDNA-encoded MRC
proteins are not completely understood, several recent studies have
pointed to an important role of nuclear respiratory factors 1 and 2
(NRF1 and NRF-2) in mediating these effects. NRF-1 and NRF-2 are
primary transcription factors of nDNA-encoded mitochondrial pro-
teins, i.e. the majority of MRC complex proteins and mitochondrial
transcription factor A (Tfam), which control transcription of the
mtDNA, are regulated by NRF-1 and NRF-2 (see below). Stirone et al.
[67] observed that long-term treatment of Ovx female rats with E2
increased NRF-1 protein in their cerebral blood vessels. Similar
stimulatory effects of E2 on NRF-2 protein levels were also seen in
heart cells ofmale rats [78]. Mattingly et al. [79] revealed an important
role of NRFs in the regulation of E2/ER-mediated biogenesis. These
investigators reported that E2 increased NRF-1 mRNA and protein in
both MCF-7 breast and H1793 lung adenocarcinoma cells in a time-
dependent manner. These effects were inhibited by ER antagonist ICI
182,780 and transcription inhibitor, actinomycin D but not by
phosphoinositide-3 kinase and MAPK inhibitors, indicating that up-
regulation of NRF-1 by E2 is mediated via ERs at the transcriptional
level. Importantly, NRF-1 promoter contains an estrogen response
element (ERE) that speciﬁcally binds to ERα and ERβ in vitro as
demonstrated by gel electrophoresis mobility shift assays (EMSA). E2
induced the recruitment of both ERα and ERβ to this ERE in vivo in
MCF-7 cells as revealed by Chip assays. Furthermore, the ERE of NRF-1
has been shown to activate expression of a reporter gene in
transfected cells. Knock down of the expression of ERα and ERβ
with respective siRNAs has revealed that it is ERα that mediates E2-
induced NRF-1 transcription in MCF-7 cells.
3.3.2. Regulation of Tfam and PGC by E2 via NRFs
Mitochondrial transcription factor A (Tfam, also named MTFA or
mtTFA) is an nDNA-encoded, mitochondrially-localized protein that is
crucial for replication, transcription and maintenance of mtDNA
[80,81]. Human Tfam binds to mtDNA in a sequence-independent
manner and is abundant enough to cover the entire mtDNA genome,
thereby stabilizing mtDNA through formation of a nucleoid (mito-
chromosome corresponding to chromosome of nDNA) and regulates
the amount of mtDNA [81]. Over-expression of human Tfam in mice
increased the amounts of mtDNA and dramatically ameliorated the
cardiac dysfunction caused by myocardial infarction [82]. Tissue-
speciﬁc knock out of Tfam in mouse heart resulted in dramatic
reduction inmtDNA content. This effect was associated with abnormal
mitochondrial functions [83]. Knock down of Tfam expression with
siRNA in HeLa cells resulted in a reduction of Tfam levels to 15% of
control, associated with a closely parallel reduction in the amount of
mtDNA [84]. Thus, Tfammay play a crucial role in maintainingmtDNA
as a main component of the nucleoid. Tfam also interacts with the
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As a key transcription factor, Tfam plays an essential role in the
activation of mtDNA transcription. Transient over-expression of Tfam
stimulated mtDNA transcription. This effect was more evident when
Tfam was transiently over-expressed in cells having less mtDNA
caused by pre-treatment with ethidium bromide [87].
Because of its important role within mitochondria, the expression
and activities of Tfam must be linked to cellular energy needs in
response to physiological, pathological changes and environmental
insults. Its expression is under the control of a number of transcrip-
tional factors, including NRF-1, NRF-2, speciﬁcity protein 1 (Sp1) and
hStaf/ZNF143. Indeed, NRF-1 and NRF-2 binding sites are present in
the proximal promoter of the human Tfam gene [80]. The promoter of
the human Tfam gene is highly dependent on both NRF-1 and NRF-2
binding sites for activity. The afﬁnity-puriﬁed factors from HeLa cells
were shown to speciﬁcally bind to these NRF-1 and NRF-2 sites.
Mutations in these contact sites eliminated NRF-1 and NRF-2 binding
and dramatically reduced promoter activity in transfected cells. NRF-1
binding appears to be the major determinant of promoter function.
This dependence on NRF-1 activation was conﬁrmed by in vitro
transcription using highly puriﬁed recombinant proteins that dis-
played the same binding speciﬁcities as the HeLa cell factors. The
activation of the Tfam promoter by both NRF-1 and NRF-2 therefore
provides a link between the expression of nuclear and mitochondrial
genes and suggests a mechanism for their coordinate regulation
during organelle biogenesis [80]. The role of NRF-1 in the regulation of
Tfam expression is further demonstrated by the observation [79] that
the E2-induced increase in NRF-1 is followed by increased Tfam and
the transcription of Tfam-regulated mtDNA-encoded COXI and NDI
genes, and increased mitochondrial biogenesis. Knock down of NRF-1
with siRNA blocked E2 stimulation of mitochondrial biogenesis and
activity, indicating a mechanism by which estrogens regulate
mitochondrial function by increasing NRF-1 expression.
In addition to NRFs, two cross-species conserved binding sites for
the transcription factor hStaf/ZNF143 have been identiﬁed within the
promoter region of human Tfam gene [88]. Promoter binding assays,
transient expression of mutant Tfam reporter gene constructs and
Chip assay had revealed that hStaf/ZNF143 was involved in promoter
activity and that the promoter of the human Tfam gene harbored a
complex organization with at least six transcriptional regulatory
elements [88].
Three binding sites for Sp1 and one for NRF-2 but none for NRF-1
are present in the proximal upstream region within the 5′-ﬂanking
region of the rat Tfam gene [89]. Transfection of a reporter gene linked
to this region into rat skeletal muscle cells has demonstrated that the
promoter activity was 10 times higher than that of control vectors.
Despite the absence of a NRF-1 binding site, co-transfection of human
NRF-1 expression vector increased the Tfam promoter activity by 2-
fold. An EMSA assay for NRF-1 has shown that NRF-1 binds to the
proximal region of the promoter between −112 and +49 [89].
Consistent with this observation, Dong et al. [90] reported that the
mRNA levels for NRF-1 and NRF-2 were 5- and 3-fold higher,
respectively, in the rapidly growing rat hepatoma relative to the
host liver, associated with more than a 10-fold increase in levels of
Tfam, and 10-, 8-, 5-, and 3-fold increases in mtDNA-encoded ND5,
ND6, COXI, COXII, respectively, the downstream targets of Tfam.
Furthermore, the DNA-binding activity of Sp1 in the hepatoma nuclear
extract was 4-fold greater than that in the liver extract.
Several studies have indicated that the expression of Tfam is
regulated by E2 via ERs. It has been reported [76,78] that E2 increased
the expression of rat cardiac PGC-1, NRF-2, Tfam and that these effects
were associated with an increase in COX IV and mtDNA-encoded COXI
and ATP synthase β-subunit, mitochondrial ATP, and COX activity in
rats that underwent trauma–hemorrhage (T–H). These effects were
totally abolished by the ER antagonist ICI-182780, indicating the
involvement of ER in mediating these effects. Furthermore, treatmentof T–H animals with ERβ-selective agonist, DPN, mimicked E2's effects
[76,78]. Similar stimulatory effects of E2 on Tfamwere seen in Kupffer
cells following T–H [91] and in human breast MCF-7 cells [79]. In
contrast, E2 was reported to inhibit the expression of Tfam and NRF-1
in cultured rat brown adipocytes [92].
The effects of E2 on the expression of Tfam are most likely
mediated via NRF-1 and NRF-2 because the promoter of human Tfam
contains functional NRF-1 and NRF-2 binding sites [80] and E2-
mediated up-regulation of NRF-1 in MCF-7 cell [79] (see above). In
addition, the effects of E2 on Tfam in heart cells may be mediated via
the interaction of NRFs with PGC-1α because it has been shown that
administration of antisense PGC-1α prevented both E2 and DPN-
mediated cardioprotection and increased levels of ATP and Tfam
following T–H and that the expression of PGC-1αwas up-regulated by
E2 and DPN [76,78]. These ﬁndings suggest that the effects of E2 on
cardiac function following T–H are mediated via ERβ up-regulation of
PGC-1α through Tfam-dependent pathway [76,78]. The effects of E2
on Tfam could be mediated via the cooperation of NRF-2 and Sp1. Sp1,
a ubiquitous transcription factor, has been shown to be involved in the
regulation of a number of estrogen-responsive genes [93,94]. Indeed,
both NRF-2 and Sp1 have been shown to occupy the NRF-2 and Sp1
binding sites on the promoter of rat Tfam gene as revealed by in vivo
genomic footprinting [90].
3.4. Regulation of protein factors involved in replication, transcription
and translation of mtDNA by NRF
The replication, transcription and translation of mtDNA into these
MRC proteins within mitochondria require the involvement of a
number of nDNA-encoded protein factors that are synthesized on
cytosol ribosomes and imported into mitochondria.
3.4.1. Regulation of protein factors involved in mtDNA replication
by NRFs
Mammalian mtDNA replication usually occurs by asymmetric
synthesis of the two strands, starting at the multiple origins in the
displacement loop (D-loop). Replication of mtDNA is carried out by
several proteins, including mitochondrial-speciﬁc DNA polymerase,
mitochondrial RNA polymerase (POLRMT), the DNA helicase TWIN-
KLE, and mitochondrial single strand binding proteins (mtSSB). DNA
polymerase γ consists of a catalytic (POLG) subunit and an accessory
(POLG2) subunit. Replication in the leading-strand origin is coupled to
transcription via the formation of an RNA–DNA hybrid known as an R-
loop [95]. POLRMT acts as lagging-strand primase in mammalian cells
and highly processes on double-stranded DNA, but synthesizes RNA
primers on a single-stranded template. The short RNA primers
synthesized by POLRMT are used by the mitochondrial DNA
polymerase γ to initiate DNA synthesis in vitro. Addition of mtSSB
reduces overall levels of primer synthesis, but stimulates primer-
dependent DNA synthesis. When combined, POLRMT, DNA polymer-
ase γ, DNA helicase TWINKLE, and mtSSB are capable of performing
simultaneous leading- and lagging-strand DNA synthesis in vitro [96].
An RNA processing enzyme, ribonucleoprotein endonuclease (RNase
MRP), is also involved in primer maturation. In vitro initiation of
leading-strand mtDNA synthesis requires the actions of RNA poly-
merase and RNase MRP for the generation of replication primers.
Mutations of the RNase MRP gene are known to cause a recessively
inherited developmental disorder, cartilage–hair hypoplasia [97].
Tfam, acting as a DNA-binding stimulatory factor, coordinates the
assembly of multiple DNAmolecules into nucleoid-like structures and
thus, is required for mtDNA maintenance [98]. Another major
replication origin is present at position 57 in the D-loop of mtDNA
in several human cell lines and immortalized lymphocytes. The
nascent chains starting at this origin do not terminate prematurely at
the 3′ end of the D-loop but proceed well beyond this control point,
behaving as “true” replicating strands. This origin is mainly
Table 2
Protein factors involved replication, transcription and transclation of mtDNA.
Processes Protein factors NRF-1 and NRF-2 binding sites Other factors Regulated by E2/ERs References
Involved in replication and
maintenance of mtDNA
POLG1 N/A
POLG2 N/A
RNase MRP NRF-1; NRF-2 [100]
Tfam NRF-1; NRF-2 Sp1 + [76–80,89–92]
Mtssb NRF-1 Sp1 [101]
hSUV3 NRF-1 Sp1 [102]
Involved in mtDNA transcription POLRMT
Tfam NRF-1; NRF-2 Sp1 + [76–80,89–92]
TFB1M NRF-1; NRF-2 [104]
TFB2M NRF-1; NRF-2 [104]
mtERF
Involved in mt mRNA translation MTIF2 NRF-1; NRF-2 Sp1; ERs [109,110]
EF-TU N/A N/A
EF-TS N/A N/A
EF-G N/A N/A
HMRF1L N/A N/A
mtRF1a N/A N/A
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whereas mtDNA synthesis from other D-loop origins may be more
important for recovery after mtDNA depletion and for accelerating
mtDNA replication in response to physiological demands [99].
The expression of several proteins involved in mtDNA replication
appears to be controlled by NRFs. As described above, the expression
of Tfam is under the control of NRF-1, NRF-2 and Sp1. Furthermore, a
functional NRF-1 site in the promoter of Rnase MRP gene [100],
functional Sp1 and NRF-1 binding sites in genes encoding the mtSSB
[101] and the human hSUV3 gene that encodes ATP-dependent RNA
and DNA helicase [102] have also been identiﬁed (Table 2).
3.4.2. Regulation of protein factors involved in mtDNA transcription
by NRFs
Using the heavy strand as the template under the control of heavy
strand promoter (HSP) within the D-loop regulatory region, mtDNA is
ﬁrst transcribed to a largemitochondrial transcript precursor.12 out of
13 mature mRNAs, two rRNAs and 22 tRNAs are derived from the
processed transcript precursor. The other mRNA that encodes for a
complex I subunit, ND4L, is transcribed using the light strand of
mtDNA as the template under the control of light strand promoter
(LSP). Transcription of mtDNA by POLRMT is initiated bidirectionally
from closely spaced promoters, HSP and LSP, within the regulatory
region (D-loop) and requires assembly of several transcriptional
factors, including Tfam, mitochondrial transcription factors B1
(TFB1M) and B2 (TFB2M). Termination factor (mTERF) is involved
in termination of mtDNA transcription (see Table 2).
As a key transcription factor, Tfam is essential for the activation of
mtDNA transcription. TFB1M and TFB2M, acting as auxiliary factors for
promoter recognition, are necessary for basal transcription of mtDNA.
They markedly enhance mtDNA transcription in the presence of Tfam
and POLRMT [103–105]. Human TFB1M and TFB2M are expressed
ubiquitously and can each support promoter-speciﬁc mtDNA tran-
scription in a pure recombinant in vitro system containing POLRMT
and Tfam. Both TFB1M and TFB2M interact directly with POLRMT, but
TFB2M is at least one order of magnitude more active in promoting
transcription than TFB1M. The presence of two proteins that interact
with mammalian POLRMT may allow ﬂexible regulation of mtDNA
gene expression in response to the complex physiological demands of
mammalian metabolism [103].
It has been established [104] that the expression of human TFB1M
and TFB2M is governed by NRF-1 and NRF-2. NRF binding sites are
present within both TFB1M and TFB2M promoters, which have been
shown to be required for maximal trans-activation by the PGC-1
family co-activators, PGC-1α and PRC. The evidence includes: a) thephysiological induction of these co-activators has been associated
with the integration of NRFs and other transcription factors in a
program of mitochondrial biogenesis; 2) the TFB1M and TFB2M genes
are up-regulated alongwith Tfam and either PGC-1α or PRC in cellular
systems where mitochondrial biogenesis is induced; and 3) ectopic
expression of PGC-1α is sufﬁcient to induce the coordinate expression
of all three nucleus-encodedmitochondrial transcription factors along
with nuclear and mitochondrial respiratory subunits. Thus, the
coordinate regulation of nDNA-encoded mitochondrial transcription
factors by NRFs and PGC-1 family co-activators is essential to the
control of mitochondrial biogenesis. Because the expression of NRFs
and PGC-1α is induced by E2 via ERα and ERβ[76,79], it is likely that
the expression of these mitochondrial transcription factors is
regulated by E2 and ERs via NRFs and PCG-1α and, perhaps, other
protein factors.
3.4.3. Regulation of proteins factors involved in mitochondrial protein
translation by NRFs
Translation of 13 mRNAs into MRC proteins occurs within
mitochondria. A number of protein factors are involved in the steps
of initiation, elongation, and termination of mitochondrial translation.
The properties of some of these factors are summarized in Table 2. The
nDNA-encoded mitochondrial translation initiation factor 2 (MTIF2)
functions to initiate the translation. The mitochondrial elongation
factor EF-Tu is a GTPase that delivers amino-acylated tRNAs to the
ribosome during the elongation step of translation. EF-Tu/GDP is
recycled by the guanine nucleotide exchange factor EF-Ts. Mitochon-
drial release factor 1α and human mitochondrial release factor 1 L
(HMRF1L) have been identiﬁed as mitochondrial translation release
factors involved in the decoding of the termination codons UAA and
UAG [106,107]. HMRF1L is methylated in the GGQ motif in vivo by the
human mitochondrial methyltransferase (HMPrmC). The methylation
of HMRF1L by HMPrmC is involved in the control of the translation
termination process, probably by preventing the undesired suppres-
sion of termination codons and/or abortive termination events at
sense codons [107].
Bot1p is also required for mitochondrial translation. Bot1p
localizes to the mitochondria and cofractionates with puriﬁed
mitochondrial ribosomes. Reduced levels of Bot1p lead to mitochon-
drial fragmentation, associated with decreased mitochondrial protein
translation, and in cell respiration. Over-expression of Bot1p resulted
in cell cycle delay, accompanied by increased cell size and cell length
and enhanced cell respiration rate. These results indicate that Bot1p
has a novel function in the control of cell respiration by acting on the
mitochondrial protein synthesis machinery [108].
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mapped to 296 bp upstream from the translation initiation site in
human heart tissue. The promoter contains binding sites for NRF-2,
Sp1, ERs and enhancer binding sites upstream. NRF-2 binds to the
NRF-2 site in the MIF2mt promoter. Reporter assays in HEK293T cells
co-transfected with an NRF-2-expressing vector and/or a MIF2
promoter reporter vector have revealed that NRF-2 trans-activated
the MIF2 promoter [109,110]. Importantly, NRF-2 sites are also present
in the promoters of several other mitochondrial translation factors,
suggesting that NRF-2 may play a key role in the regulation of mito-
chondrial protein synthesis [110]. The presence of Sp1 and ER binding
sites in the promoter ofMTIF2 gene suggests that the expression of this
gene can be directly activated by E2 via ERs, Sp1 and NRFs.
3.5. Regulation of mtDNA transcription and translation by estrogens/ERs
The presence of ERα and ERβ in mitochondria suggests that these
mitochondrial ERs are directly involved in E2-induced mtDNA
transcription. The D-loop, the major regulatory region, of mtDNA
contains four putative estrogen-responsive elements (mtEREs)
[111,112]. Using EMSA, supershift assays and surface plasma resonance
(SPR), Chen et al. [52] have demonstrated that ERα, ERβ and
mitochondrial proteins that contain ERβ speciﬁcally bind to these
mtEREs. E2 dose- and time-dependently enhanced the binding of
MCF-7 cell mitochondrial proteins to these mtEREs. It is likely that E2
stimulates the interaction of ERα and/or ERβ with Tfam, TFB1M,
TFB2M and other factors within mitochondria, and form active
transcription complex, thus enhancing mtDNA transcription. Because
E2 stimulates the expression of Tfam, and possibly TFB1M and
TFB2M via activation of NRF-1 and NRF-2, it is likely that E2 and ERs
stimulate the transcription via activation of the expression of these
mitochondrial transcriptional factors. On the other hand, E2 may
activate the expression of several key proteins involved in mitochon-
drial protein translation and thus, enhance the rate of mitochondrial
proteins synthesis. The direct effects of E2 and ERs on the control of the
expression of protein factors involved in mitochondrial protein transla-
tion and the mechanisms involved deserve further investigation.
4. Regulation of nDNA-encoded MRC proteins by E2 via NRFs
As mentioned above, the majority of MRC proteins are encoded by
nDNA, synthesized on cytosol ribosomes and then imported into
mitochondria where they are assembled with 13 mtDNA-encoded
proteins into the four MRC complexes and mitochondrial ATP
synthase. Previous studies that suggest that estrogens are involved
in the regulation of nDNA-encoded MRC proteins have been reviewed
[46,113]. A number of recent studies have provided a strong support
for a key role of ERα and ERβ in the regulation of E2-induced
expression of nDNA genes encoding MRC proteins in a variety of cells
and tissues.
4.1. Regulation of nDNA-encoded MRC proteins by estrogens/ERs
Chen et al. [48,114] reported that treatment of female rats with EE
and HepG2 cells with E2 enhanced the transcript levels of a nuclear
gene encoding H+-ATP synthase subunit ɛ. Gene expression proﬁling
[115] of prostate from E2 plus testosterone-treated Noble rats revealed
the enhanced expression of several nuclear genes encoding MRC
complex subunits, including COXVa, COXVIa and mitochondrial H+-
ATP synthase subunits b and f. O'Lone et al. [116] performed gene
expression proﬁling in mouse aorta of ERα knockout (ERαKO) and
ERβKO mice to identify comprehensive gene sets whose expression
was regulated by long-term E2 treatment. They treated ERαKO and
ERβKO mice with E2 for 1 week and then performed microarray
analysis for identiﬁcation of ER subtype-dependent gene expression.
Their data revealed that ERα- and ERβ-dependent pathways regulateddistinct and largely non-overlapping sets of genes, i.e. ERα was
essential for most of the E2-mediated increase in gene expression in
wild-type aortas whereas ERβ mediated nearly 90% of E2-mediated
decreases in gene expression. The E2-regulated genes include those
encoding for MRC complexes (see Table 1A,1B,1C,1D,1E), for proteins
involved in ROS pathways and extracellular matrix synthesis.
Importantly, the E2/ERβ pathway mediated down-regulation of
mRNAs for nuclear genes encoding subunits for all ﬁve MRC
complexes in mouse aorta. Using a combined proteomic and
functional biochemical approach, Nilsen et al. [77] determined the
overall impact of E2 on mitochondrial protein expression and
functions in neurons of rat brain. They treated Ovx adult female rats
with a single injection of E2 for 24 h, puriﬁed neuron mitochondria
and then conducted two-dimensional gel electrophoresis and liquid
chromatography-tandem mass spectrometry to screen the E2-
mediated changes in mitoproteome. The proteomic analyses revealed
a twofold or greater change in expression of 66 proteins. Of these, 28
proteins were increased in expression after E2 treatment whereas 38
proteins were decreased in expression relative to control. E2 enhanced
several key metabolic enzymes, including the subunits for MRC
complex IV and ATP synthase subunits (Table 1D and 1E) aswell as the
TCA cycle enzymes. Consistent with the increased gene expression is
the increased respiratory control ratio, elevated complex IV activity, in
association with simultaneous reduction of free radical generation in
brain. Arajo et al. [117] examined E2 effects on MRC gene expression
and the MRC activity of rat cortical and mesencephalic astrocytes.
They observed that MRC structural and functional properties were
regulated dependent on the E2 exposure time and the brain region, but
independent of the nuclear ERs. They demonstrate that long-term E2
exposure increases the expression of genes for MRC complex subunits
and the mtDNA content, thereby indicating an up-regulation of the
amount of mitochondria per cell together with an increase of MRC
production. This could represent an important indirect mechanism by
which long-term estrogen exposure protects neurons from cell death
under neurotoxic conditions. On the other hand, they observed short-
term effects of estrogen on the activity of mitochondrial, proton-
pumping MRC complexes. In astrocytes from the cortex, MRC activity
was decreased, whereas it was increased in astrocytes from the
mesencephalon. An increased production of ROS would be the
consequence of an increased MRC activity in mesencephalic astro-
cytes. This could explain the different efﬁciencies of estrogen-
mediated short-term protection in distinct brain regions, but also
indicates the limitations for a therapeutic short-term application of
estrogen. Razmara et al. [118] observed that treatment of cultured
human brain microvascular endothelial cells with E2 for 24 h
increased mitochondrial cytochrome c protein and mRNA. These
effects weremediated via ERα as demonstrated by their being blocked
by knocking down ERα expression with ERα siRNA but not by
knocking down ERβ expression with ERβ siRNA. Direct measurement
of mitochondrial superoxide with MitoSOX Red showed that 17β-
estradiol, but not 17α-estradiol, signiﬁcantly decreased superoxide
production, whichwas blocked by the ER antagonist, ICI182780. Use of
selective ER agonists also demonstrated that the decrease in
mitochondrial superoxide was mediated by ERα but not ERβ. The
stimulation of nDNA-encoded MRC genes by E2 was also seen in
human breast MCF-7 cells [79,119].
4.2. Role of NRFs and other transcription factors in E2-induced
transcription of nDNA-encoded MRC proteins
Transcriptional coordination of nDNA-encoded subunits for four
MRC complexes and mitochondrial ATP synthase is likely accom-
plished by transcription factors responding to upstream signals. The
transcription activity of the promoters in most of the ubiquitous genes
encoded for MRC proteins is regulated by factors binding to the 5′
upstream NRF-1, NRF-2, Sp1 and YY1 sites. Among these, NRF- and
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coordinate regulation of the expression of MRC complexes and F0–F1
ATP synthase.
4.2.1. Role of NRFs in control of complex II protein expression
The promoters of nDNA-encoded genes (SDHA, SDHB, SDHC and
SDHD) of complex II have been cloned and analyzed. NRF-1 and NRF-2
binding sites have been identiﬁed in the promoter regions of all four
genes (Table 1B) [18,19,120–122]. Reporter gene analysis, site-directed
mutagenesis and EMSA have revealed that both NRF-1 and NRF-2
were required for SDHB gene expression [120]. It has been also
demonstrated that NRF-1 bound to the promoters of SDHA and SDHD
genes and that the activity of complex II was dynamically regulated
through the catalytic SDHA ﬂavoprotein [122].
4.2.2. Role of NRFs in the control of nDNA-encoded genes for complex
IV and its assembly
As mentioned above, complex IV consists of proteins that are
bigenomically encoded. Of its thirteen subunits, three are encoded in
the mtDNA and ten are encoded in the nDNA. Transcriptional
coordination of ten nuclear-encoded COX subunit genes is likely
accomplished by transcription factors responding to upstream signals.
The functional nDNA-encoded genes for the COX subunits,
including IV, Vb, VIa ‘L’ and ‘H’, VIIa ‘L’ and ‘H’, VIIc and VIII (H), from
different mammalian species and their 5′ ﬂanking putative promoter
regions have been sequenced and extensively characterized [123–127].
The promoters of several genes for COX assembly (e.g. COX17P and
SURF1) have also been characterized [128,129]. While the ubiquitous
COX genes and assembly genes show extensive heterogeneity in their
promoter regions, one common feature is that the majority of these
genes containmultiple transcription initiation sites for both general as
well as the specialized transcription factors NRF-1, NRF-2, Sp1 and YY1
(Table 1D). A number of studies [123–134] have demonstrated that
NRF-1, NRF-2, Sp1 and YY1 bind to the corresponding sites in gene
promoters and activate the transcription of these genes.
Since the nuclear genes encoding 10 subunits for COX are localized
in different chromosomes, several studies [130,135,136] were per-
formed to address whether the 10 nuclear genes are transcribed
simultaneously and whether a single transcription factor binds to all
ten of COX subunit promoters. Dhar et al. [136] performed in silico
analysis of murine nDNA-encoded COX subunit promoters and
identiﬁed NRF-1 binding sites in all ten promoters, that are highly
conserved among mice, rats, and humans. Using EMSA, supershift
assays and site-directed mutagenesis, they demonstrated that NRF-1
binds to all ten promoters. Moreover, using in vivo ChIP assays, they
also showed in murine neuroblastoma cells that NRF-1 bound to all
ten promoters. Furthermore, they observed that silencing NRF-1
expression with siRNA reduced all ten COX subunit mRNAs and
mRNAs of other genes involved in mitochondrial biogenesis. These
results indicate that NRF-1 plays a signiﬁcant role in coordinating the
transcriptional regulation of all ten nuclear-encoded COX subunits in
neurons.
Putative NRF-2 binding sites were also identiﬁed on all ten nDNA-
encoded COX gene promoters in the rat genome. A study by
Ongwijitwat et al. [135] provided several lines of evidence demon-
strating that NRF-2 is also an important mediator for coordinated
regulation of all ten nuclear-encoded COX subunit genes: 1) NRF-2
binds in vivo to six of the ten nDNA-encoded COX subunit promoters
as revealed by in vivo ChIP assay; 2) NRF-2 also binds to the other four
subunits as shown by EMSA, super shift assays, and promoter
mutation study; 3) COX expression is signiﬁcantly reduced by
transfection of dominant-negative constructs of NRF-2 proteins; and
4) more importantly, NRF-2 has been shown to sense changing
cellular energy demands in rat neurons and the silence of its
expression down-regulates cytochrome oxidase and other target
gene mRNAs [130].It is interesting to note that the promoters of the heart- and
muscle-speciﬁc COXVIα (H) and COXVIIα (H) do not contain NRF-1
and NRF-2 sites but, instead, have conserved myocyte enhancer factor
2 (MEF2) elements. It has been shown [137,138] that the expression
and functional activity of MEF2 is under the control of NRF-1. First,
over-expression of NRF-1 inducedMEF2AmRNA levels. TheMEF2A 5′-
regulatory region contains an evolutionarily conserved canonical
element that binds endogenous NRF1 in ChIP assays; second, NRF-1
regulated MEF2A promoter-reporters as demonstrated by the stimu-
latory effects of its over-expression, the suppressive effects of its
under-expressionwith siRNA, and by promoter mutation studies; and
third, ChIP assays using isoform-speciﬁc antibody to four mammalian
MEF2 isotypes conﬁrmed speciﬁc MEF2A binding to the COX6A(H)
promoter. These ﬁndings support a role for MEF2A as an intermediary
in coordinating respiratory chain subunit expression in heart and
muscle through a NRF1→MEF2A→ COX(H) transcriptional cascade.
MEF2A also binds theMEF2A and PPARGC1A promoters in ChIP assays,
placing it within a feedback loop with PGC-1α in controlling NRF1
activity. Interruption of this cascade and loop may account for striated
muscle mitochondrial defects in mef2a null mice [137,138].
The PGC-1 family of regulated co-activators (PGC-1α, PGC-1β and
PRC) plays an important role in directing respiratory gene expression
in response to environmental signals. PRC and PGC-1α differ in their
interactions with nuclear hormone receptors but are highly similar in
their direct binding to several nuclear transcription factors implicated
in the expression of the MRC proteins. Vercauteren et al. [139]
observed that the NRF-2 subunits and PRC were co-immunoprecipi-
tated from cell extracts, indicating that the two proteins exist in a
complex in vivo. The association between PRC and NRF-2 is mediated
by HCF-1 (host cell factor 1), a major chromatin component. Both PRC
and NRF-2 bind to HCF-1 in vitro and in vivo and their associationwas
required for PRC trans-activation through promoter-bound NRF-2.
NRF-1 and NRF-2 are known to activate several mitochondrial
transcription factors including Tfam, TFB1M and TFB2M (see above).
NRF-2, PRC and HCF associate with NRF-2-dependent nuclear genes
that direct the expression of TFB1M and TFB2M. Short hairpin RNA-
mediated knock down of PRC protein levels led to reduced expression
of TFB2MmRNA and mitochondrial transcripts for COXII and cytb and
these changes in gene expression coincided with a marked reduction
in COX activity [139].
NRF-1 and NRF-2 in cooperationwith co-activators such as PGC-1α
and related factors HCF-1 are directly involved in the regulation of 10
nDNA-encoded subunits and indirectly regulate, via activating
mitochondrial transcription factors, e.g. Tfam, TFB1M and TFB2M,
and the expression of the three mtDNA-encoded COX subunits. Thus,
NRF-1 and NRF-2 prove to be the two key bigenomic coordinators for
transcriptional regulation of all COX subunits in neurons. Because the
transcription of NRF-1, NFR-2, PGC-1α are up-regulated by E2 via ERs
[67,78,79], the effects of E2/ER on the transcript levels of both nDNA-
and mtDNA-encoded subunits of COX are likely mediated through
these factors.
4.2.3. Role of NRFs in control of nDNA-encoded genes for complexes I,
III and mitochondrial ATP synthase and their assembly
While much less is known about the role of NRFs, Sp1 and other
transcription factors in the control of the expression of the nDNA-
encode genes for complexes I, III and V and their assembly proteins,
NRF-1, NRF-2, Sp1 and YY-1 binding sites have been identiﬁed in the
promoters of a few genes for complex I (e.g. NDUFV1 and NDUFS8)
(Table 1A) [140–143], and mitochondrial ATP synthase (e.g. ATPγ)
(Table 1E) [144]. There are no reports, to date, for the presence of
binding sites for NRF-1, NRF-2, Sp1 and YY-1 in the promoters of
nDNA-encoded complex III genes. Several studies have demonstrated
that the NRF-1 and/or NRF-2 are capable of binding to these sites in
the promoters of NDUFV1, NDUFS8 and ATPγ genes and activate their
transcription [141,143,144]. It has been demonstrated [140,142] that
Table 3
nDNA-encoded TOMs involved mitochondrial protein import machinery.
Genes Properties
NRF-1 and NRF-2
binding sites
Other
factors
Regulated
by E2/ERs
References
nDNA-encoded TOM20 NRF-1 N/A N/A [149–150]
TOM40 N/A N/A N/A
TOM70 NRF-1; NRF-2 N/A N/A [151–152]
TOM34 NRF-1; NRF-2 N/A N/A [153]
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5. Regulation of mitochondrial import machinery by NRFs
The majority of nuclear-encoded, mitochondrially-localized pro-
teins, including the nDNA-encoded MRC proteins and the protein
factors that are involved in mtDNA replication, transcription and
translation and MRC assembly proteins (Tables 1A–E and 2), are
synthesized on cytosol ribosomes with N-terminal signal sequences
termed pre-sequences or internal targeting signals, and then imported
into mitochondria. Precise targeting of mitochondrial precursor
proteins to mitochondria requires Translocase of the Outer mitochon-
drial Membrane (designated Tom), a multi-subunit complex contain-
ing speciﬁc import receptors. Three important Toms, namely Tom20,
Tom22, and Tom70, are anchored in the outer membrane by a single
transmembrane α-helix, located at the N-terminus in the case of
Tom20 and Tom70 (signal-anchored) or in the C-terminal portion in
the case of Tom22 (tail-anchored), where they serve as receptors for
speciﬁc recognition and membrane translocation of nuclear-encoded
preproteins [145]. Each Tom binds to individual mitochondrial
preproteins with different speciﬁcity. Tom20 recognizes preferentially
mitochondrial pre-sequences, and preproteins with internal targeting
signals. Generally, preproteins with pre-sequences are initially
recognized by Tom20 and, subsequently, by Tom22. It has been
shown that the cytosolic domains of Tom20 and Tom22also function to
maintain their substrate preproteins unfolded and prevent them from
aggregation on the mitochondrial surface. The cytosolic domain of
Tom22 appears to function as a receptor in cooperationwith Tom 20. It
has been shown that Tom20 and Tom22 are apparently involved in the
same step or sequential steps along the same pathway of targeting
signal recognition in import [145]. The hydrophobic preproteins with
internal targeting signals are ﬁrst recognized by Tom70, which then
associates with molecular chaperones, thereby maintaining their
substrate preproteins in an import-competent state [146–148]. In
addition to these Toms, the human Tom34 gene encodes a cytosolic
protein with chaperone-like activity that helps import some pre-
proteins to the mitochondria by keeping them in an unfolded, import-
compatible state.
All of the Tom proteins are encoded by nuclear genes, synthesized
as precursors on the cytosol ribosomes and then translocated to the
outer mitochondrial membrane. The channel-forming β-barrel pro-
tein Tom40 is targeted tomitochondria via Tom receptors and inserted
into the outer membrane by the sorting and assembly machinery
(SAM complex). A further outer membrane protein, Mim1, plays a less
deﬁned role in assembly of Tom40 into the Tom complex. These Toms
are anchored in the outer membrane: insertion of the precursor of
Tom22 into the outer membrane requires pre-existing Tom receptors.
Mim1 is required for efﬁcient membrane insertion and assembly of
Tom20 and Tom70, but not Tom22. Mim1 associates with SAM (core)
components to a large SAM complex, explaining its role in late steps of
the assembly pathway of Tom40. Thus, Mim1 is not only required for
biogenesis of the beta-barrel protein Tom40 but is also required for
membrane insertion and assembly of signal-anchored Tom receptors.
Thus, Mim1 plays an important role in the efﬁcient assembly of the
mitochondrial Tom complexes.
Because Tom complexes act as the central entry gate for nDNA-
encoded mitochondrial precursor proteins, the biogenesis of the
mitochondrial Tom complex is subjected to strict control. NRF-1 and
NRF-2 are involved in the regulation of the expression of the
mitochondrial Tom20, Tom22, Tom70 and Tom34.
NRF-2 has been shown to be critical for maintaining normal
transcriptional levels of the Tom20 gene. Blesa et al. [149] identiﬁed a
NRF-2 and two NRF-1 bindingmotifs in the promoter of human Tom20
gene. Using Chip assays and reporter assays in HeLa S3 and A204 cells,
they demonstrated that only NRF-2 and the proximal NRF-1 motifswere involved in the expression of the gene. The NRF-2 binding site
was required to activate transcription. The proximal NRF-1 site
cooperated with NRF-2 in regulating the expression of the gene
whereas the distal NRF-1 binding site was not functional.
Blesa et al. [150] identiﬁed two NRF-2 binding motifs in the 5′-
ﬂanking region of the human Tom70 gene. This region contained
thirteen potential CpG methylation sites, three of which occur in the
sequence 5′-CCGG-3′. Interestingly, each NRF-2 site contained one
CCGG sequence. Reporter assays in HeLa cells, Chip assays, site-
directed mutagenesis, and EMSA assays demonstrated that NRF-2
bound in vivo to the Tom70 promoter and that interactions between
these sites and a CpG island contributed to expression. Furthermore,
the two NRF-2 binding sites of the promoter have different functional
contributions in promoting TOM70 expression, i.e. they worked in an
additive manner as single sites [151]. Site-speciﬁc methylation of the
NRF-2 binding sites in the Tom70 promoter reduced the expression
of a luciferase reporter in HeLa S3 cells. Abrogation of NRF-2 binding
at the methylated sites was conﬁrmed by EMSA assays. These results
have established essential role of the NRF-2 binding sites for
promoter activity of Tom70 [152]. However, studies of methylation
on DNAs from different sources found no methylation in the
promoter regions of Tom70 and other Tom/TIM family genes. Thus,
although in vitro methylation inactivates the expression of Tom70,
these results suggest that this is not the mechanism modulating its
expression in vivo. Since a number of nuclear genes encoding
mitochondrial translocases have NRF-2 binding sequences containing
CpG methylation sites, it is possible that methylation/demethylation
of the NRF-2 binding sites might be a regulatory mechanism of
mitochondrial biogenesis [152].
Blesa et al. [153] reported the existence of binding sites for NRF-1,
NRF-2 and Sp1 in the 5′ region of the human Tom34 gene. Site-
directed mutations at these sites on promoter activity in HeLa S3 and
A204 cells, in conjunction with Chip assays, EMSA assays, and in vivo
methylation analysis of the promoter region have demonstrated that
NRF-1 is the main transcription factor regulating the expression of
Tom34. Sp1 interacts with NRF-1 to stimulate the promoter's full
activity. Tom34 is over-expressed frequently in colorectal tumors,
suggesting that it has a role in the growth of cancer cells. In this
context, Tom34 is a potential target for novel anti-cancer drugs, and it
might also be used in the diagnosis of colorectal cancer.
In summary, NRF-1 and NRF-2 are involved in the regulation of
the expression of nuclear genes encoding: 1) MRC complex subunits,
ATP synthase and their assembly proteins; 2) proteins required for
replication, transcription and translation of mtDNA; and 3) proteins
involved in mitochondrial protein machinery. Therefore, NRFs
coordinate the expression of nuclear and mitochondrial genes
involved in mitochondrial biogenesis and respiration. The nucleo-
mitochondrial interactions depend on the interplay between NRF-1,
NRF-2 and other transcriptional factors including Sp1, MEF2, and
other members of the PGC-1 family of regulated co-activators (e.g.
PGC-1α and PRC). The transcription factors target genes that specify
the MRC, the mitochondrial transcription, translation and replication
machinery, and protein import and assembly apparatus among
others. These transcriptional paradigms provide a basic framework
for understanding the integration of mitochondrial biogenesis and
function with signaling events that dictate cell- and tissue-speciﬁc
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activated by E2 via ERs, and Sp1 acts as a transcription factor in
regulating the expression of a number of estrogen-responsive genes,
ERs, Sp1 and other transcription factor are likely involved in E2-
mediated coordinate regulation of 1) MRC complex subunits and
their assembly proteins; 2) proteins required for replication,
transcription and translation of mtDNA; and 3) proteins involved in
mitochondrial protein import machinery and 4) mtDNA-encoded
MRC proteins Table 3.
6. MRC as an important regulator of apoptosis and cell
proliferation
In addition to playing important roles in intracellular energy
generation and redox-dependent intracellular signaling, mitochon-
dria are the focal points of a variety of key events in apoptosis,
including the release of caspase activators (e.g. cytochrome c),
changes in electron transport, loss of mitochondrial transmembrane
potential, altered cellular oxidation–reduction, and regulation of pro-
and anti-apoptotic Bcl-2 family proteins. The different signals that
converge on mitochondria to trigger or inhibit these events and their
downstream effects delineate several major pathways in physiological
cell death [154]. As an important structural and functional part ofFig. 3. Genetic and pharmacological evidence for MRC as modulator of apoptosis. (A) Correla
RC components of the cybrids are depicted. WTcells have a full complement of RC complexes
reduced complex I (depicted as a smaller circle). CYTB cells are missing complex III and have
gel, but have some residual ATP hydrolytic complex V activity. NARP cells have all of the com
induction is represented by +, high response by +++, and low response by− (adapted fr
Evidence for MRC as Modulator of Apoptosis: effects of speciﬁc inhibitors on individual co
shown. Inhibition of individual complex is represented by X; Normal response to apoptosismitochondria, the MRC plays a key role in the regulation of cell
proliferation and apoptosis, and thus may be involved in tumor
progression, as supported by the several lines of genetic and
pharmacological evidence.
6.1. Evidence for the MRC as an important regulator of apoptosis
6.1.1. Genetic evidence
As described in Section 3.2 Induction of mtDNA transcription by E2
and ERs, Tfam is essential for replication, transcription and main-
tenance of mtDNA. It has been observed [83] that tissue-speciﬁc
knockout of Tfam inmouse heart caused dramatic reduction inmtDNA
and a severe MRC deﬁciency. These effects are associated with
increased in vivo apoptotic cardiocytes. Over-expression of Tfam in
transgenic mice ameliorated the decreased mtDNA copy number and
MRC enzyme activities in post-myocardial infarction hearts and
signiﬁcantly increased survival rate and decreased apoptosis [82].
Kwong et al. [155] has clearly demonstrated a correlation between
MRC composition and apoptotic responses. These researchers inves-
tigated the role of MRC dysfunction in the control of apoptosis, using
mtDNAmutations as geneticmodels. Six genetic models were used: 1)
wild-type cell with full complements of the MRC complexes I, II, III, IV
and V; 2) ρo cells that are missing complexes I, III, IV, V but retaintion between MRC Composition and Apoptotic Response in mtDNA Mutant Cybrids. The
. 0 cells are missing complexes I, III, IV, and V. COX cells are missing complex IV and have
reduced complex I. MERRF cells are missing complexes I, III, IV, and V, detectable by BN
plexes in place, but have reduced amounts and activities. Normal response to apoptosis
om Kwong et al. [155] with permission granted by J. Cell. Biology). (B) Pharmacological
mplexes. Induction of apoptosis by inhibitors speciﬁc for individual MRC complexes is
induction is represented by +.
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complex I activities; 4) CYTb cells that are missing complex III; 5)
MERRF cells that are missing complexes I, III, IV, but have some
residual ATP hydrolytic complex V activity; and 6) NAPP cells that
have all the MRC complexes in place but have reduced amounts and
activities. The responses of these cells to both mitochondrial (MT)-
and endoplasmic reticulum (ER) stress-induced apoptosis are sum-
marized in Fig. 3A. There are signiﬁcant differences among these cell
models in responses to apoptotic stimuli: cells lacking MRC are
protected against both MT- and ER stress-induced apoptosis. Cells
with MRC, but unable to generate electron ﬂux, are protected against
MT-apoptosis, although they have increased sensitivity to ER stress
and cells with a partial reduction in electron ﬂux have increased
apoptosis under both conditions. These results have shown that the
MRC modulates apoptosis in a context-dependent manner indepen-
dent of ATP production and that apoptotic responses are the result of
the interplay between mitochondrial functional state and environ-
mental cues.
Several studies have also demonstrated that over-expression of
individual MRC proteins led to suppression of apoptosis. Bcl-2-
associated×protein (Bax) and its related protein, Bak, are pro-
apoptotic proteins involved in cell death. Both proteins are essential
for maximum apoptotic response induced by several apoptotic
inducers including tumor necrosis factor-α (TNF-α) [156], curcumin
(a polyphenolic compound and cancer chemopreventive agent) [157]
and sulforaphane (a cruciferous vegetable-derived cancer chemopre-
ventive agent) [158]. Human MRC complex IV subunit VIa (COX6A1)
was identiﬁed as a novel suppressor of Bax-mediated cell death in
yeast [159]. Over-expression of COX6A1 signiﬁcantly suppressed Bax-
and N-(4-hydroxyphenyl) retinamide (4-HPR)-induced apoptosis in
yeast and human glioblastoma-derived U373MG cells. The ROS
generation in response to Bax or 4-HPR was inhibited in yeast and
U373MG cells expressing COX6A1, indicating that COX6A1 exerts a
protective effect against ROS-induced cell damage. 4-HPR-induced
mitochondrial translocation of Bax, mitochondrial cytochrome c
release, and activation of caspase-3 were markedly attenuated in
U373MG cells that stably expressed COX6A1. These results demon-
strate that over-expression of MRC proteins, e.g. COX6A1, has a
potential role in protecting mammalian cells from 4-HPR-induced
apoptosis.
6.1.2. Pharmacological evidence
A large number of studies with MRC complex-speciﬁc inhibitors
and chemotherapy reagents that speciﬁcally target individual MRC
complexes have provided strong evidence for the MRC as an
important regulator of apoptosis (Fig. 3B). For example, it has been
shown that inhibition of complex I with rotenone [160–163] and
chemotherapeutic reagents e.g. arsenic trioxide [162,164], and TNF-α
[165], and ceramide [166] causes increased MRC-derived ROS
generation, leading to apoptosis characterized by induction of
mitochondrial membrane permeability transition (MPT), cyto-
chrome c release, activation of various caspases and DNA fragmenta-
tion. Inhibition of complex II with speciﬁc inhibitors, e.g. 3-
nitroproprionic acid [167], and alpha-tocopheryl succinate (a vitamin
E analogue) [168–172], also causes apoptosis. Benzyl isothiocyanate
(BITC) is a dietary cancer chemopreventive agent that causes apoptosis
in breast cancer cells [173]. The BITC-induced apoptosis was initiated by
MRC-derived ROS via regulation by Bax and Bak in breast cancer cells
[173,174]. Xiao et al. [175] demonstrated that the BITC-induced
apoptosis in these cells was initiated by ROS due to its inhibition of
complex III. Inhibition of complex III with antimycin A induced
apoptotic effects in lung cancer cells [176]. Complex III is a target of
C2-ceramide [177], which induced apoptosis in lung cancer cells [178].
Lyssaviruses are highly neurotropic viruses. The matrix proteins
of some lyssaviruses strongly induced neuronal apoptosis. Gholamic
et al. [179] reported that for Mokola virus (MOK), the M(M-MOK),targeted mitochondria, disrupted the mitochondrial morphology, and
induced apoptosis by its physical associationwith the COXI of complex
IV. N-retinyl-N-retinylidene ethanolamine (A2E) is a compound
suspected to cause age-related macular degeneration. A2E has been
shown to interferewith the binding of cytochrome c to COX, detaching
pro-apoptotic proteins from mitochondria, and inducing apoptosis in
mammalian retinal pigment epithelial cells [180,181].
Most human carcinomas contain reduced levels of the catalytic
subunit of the mitochondrial ATP synthase. In colon and lung cancers,
this alteration correlates with a poor patient prognosis. Down-
regulation of the H+-ATP synthase has been shown to link to the
resistance of the cells to chemotherapy [182]. It has been shown that
inhibitors of the ATP synthase delayed staurosporine-induced apop-
tosis in liver cells that are dependent on oxidative phosphorylation for
energy provision [182]. Roy et al. [183] observed that 3,3′-Diindo-
lylmethane (DIM) inhibited mitochondrial ATP synthase of Leishma-
nia donovani and induced apoptosis in protozoan parasites. DIM-
induced inhibition of ATP synthase activity caused depletion of
mitochondrial ATP levels and a signiﬁcant stimulation of mitochon-
drial ROS production, followed by depolarization of mitochondrial
membrane potential (Deltapsim). Since Deltapsim is the driving force
for mitochondrial ATP synthesis, loss of Deltapsim results in depletion
of the cellular ATP level. The loss of Deltapsim caused the cellular ROS
generation and in turn led to the oxidative DNA lesions followed by
DNA fragmentation. On the other hand, loss of Deltapsim led to release
of cytochrome c into the cytosol and subsequent activation of the
caspase-like proteases, which led to oligonucleosomal DNA cleavage.
They have also shown that mtDNA-depleted cells were insensitive to
DIM to induce apoptosis. Therefore, mitochondria are necessary for
cytotoxicity of DIM. These results indicate that DIM-induced mito-
chondrial dysfunction by inhibition of ATP synthase activity leads to
apoptosis in Leishmania parasites.
The genetic and pharmacological studies described above strongly
support the notion that up- and down-regulation of the MRC
biogenesis and functions are closely related to the control of
apoptosis: up-regulation of the MRC biogenesis/function inhibits
apoptosis and stimulate cell growth and proliferation whereas their
down-regulation and/or inhibition induces apoptosis and inhibition
cell growth and proliferation. Physiological, pathological and environ-
mental factors that cause dramatic and persistent changes in the MRC
biogenesis and functions may alter the balance of the cell growth and
cell death.
6.2. Mitochondrial permeability transition pore as mediator of
apoptosis and its regulation by E2/ERs
Cellular stresses, such as ischemia, hypoxia, oxidative stress, and
cytotoxic drugs induce a cascade of events at the level of the
mitochondrion that, if left unchecked, will kill the cell. Initially this
involves excessive production of ROS, and Ca2+ overload of the
mitochondrial matrix [184–187]. This in turn causes permeabilization
of the inner mitochondrial membrane. This phenomenon, termed the
mitochondrial permeability transition (MPT), dissipates the proton
electrochemical gradient (Wm) that drives many mitochondrial
functions, leading to ATP depletion, further ROS production, and
ultimately swelling and rupture of the organelle [184–187]. This in
turn releases pro-apoptotic inter-membrane space proteins, most
notably cytochrome c, Smac/DIABLO, htrA2/Omi protease, and
endonuclease-G [184,188]. The coordinated action of these proteins
subsequently results in the death of the cardiomyocyte by apoptosis.
However, if the stress is severe and/or prolonged, ATP will be depleted
and the cell will instead undergo necrosis. Indeed, the relative
contribution of MPT to apoptosis versus necrosis is still the subject
of debate [189].
The mitochondrial permeability transition pore (MPTP), a non-
speciﬁc channel thought to span both mitochondrial membranes,
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permeability [184–187]. The pore itself is permeable to solutes up to
1.5 kDa. This causes equilibration of H+ across the inner membrane,
which dissipates Wm and inhibits ATP production. A concomitant
inﬂux of water causes swelling of the mitochondria, which stretches
the membranes to the point where the outer membrane fails. The
mitochondrial pore is redox, Ca2+, voltage, adenine nucleotide, Pi, and
pH sensitive [184–187]. Most importantly, increases in matrix Ca2+
and ROS induce pore opening, whereas adenine nucleotides inhibit
the pore; and many diseases are associated with increases in
mitochondrial pore activators (Ca2+, ROS) and reductions in mito-
chondrial pore inhibitors (ATP/ADP). Indeed, studies have shown that
inhibition of the MPTP blunts ischemia–reperfusion injury in multiple
organs [190–193], and can also protect against the cell loss that
underlies heart failure [194,195], muscular dystrophy [196,197], cancer
drug-induced toxicity [198,199], and several neurodegenerative
diseases [199–201].
Unfortunately, the precise molecular architecture of the MPTP
remains unknown. Based upon biochemical and pharmacological
studies, the pore was proposed to consist of the voltage-dependent
anion channel (VDAC) in the outer membrane, the adenine
nucleotide translocase (ANT) in the inner membrane, plus CypD in
the matrix (1–4). VDAC, ANT, and CypD interact at membrane
contact sites and reconstitution of this complex in vesicles yields a
Ca2+-sensitive channel reminiscent of the mitochondrial pore [202].
However, recent genetic studies have seriously questioned the
validity of this paradigm. While several studies have shown that
mice lacking CypD are resistant to Ca2+- and ROS-induced MPT and
cell death in the heart and other tissues [190,203,204], mice lacking
ANT still exhibit a classical permeability transition phenomenon and
respond normally to death-inducing stimuli [205]. Baines et al. have
also shown that deletion of all 3 VDAC isoforms does not inactivate
the mitochondrial pore nor prevent cell death [206]. Therefore, CypD
is the only deﬁned molecular component of the MPTP, where it
functions in an enzymatic capacity to induce pore formation and cell
death by binding and regulating unknown proteins. Consequently,
there is now a concerted effect to identify novel components of the
mitochondrial pore by a variety of proteomic and genetic screening
methodologies.
The ability of estrogens and mitochondrial ERs to modulate MPTP
has not been extensively studied. However, evidence that estrogen
and its receptors can directly (i.e., non-genomically) inﬂuence MPT is
beginning to accumulate. Using the well-established technique of
mitochondrial swelling, Morkuniene et al. demonstrated that direct
application of physiological concentrations of either E2 or 4-hydro-
xytamoxifen to rat cardiacmitochondria could suppress Ca2+-induced
permeability transition [207]. Similarly, Custodio et al. reported that
tamoxifen could prevent Ca2+-induced mitochondrial swelling, Wm
collapse and matrix Ca2+-release, all indices of MPT, in isolated liver
mitochondria [208,209]. Comparable effects have also been observed
in brain mitochondria [210].
These exciting ﬁndings have been extended to intact cells. E2 has
been shown to prevent MPT in CHO cells (Miyaguchi) [211], neurons
[210,212], cervical epithelia [213], and lens epithelia [59]. Antitheti-
cally, withdrawal of E2 induces MPT in human breast cancer cells
[214]. The one caveat with these studies is that they primarily used
changes in Wm as their index of MPT. While opening of the
mitochondrial pore will indeed dissipate Wm, alterations in Wm can
still occur independently of pore opening, and therefore are not the
most reliable way of observingMPT in intact cells. Instead, the calcein/
CoCl2 method developed by Bernardi et al. is a more reliable
measurement of permeability transition in intact cells [215], and
studies examining the anti-permeability transition effects of E2 using
this technique are needed.
The most obvious question is how does E2 and its analogues
modulate the mitochondrial pore. Although in intact cells this ismost likely a multi-factorial process involving both genomic and non-
genomic pathways, the fact that E2 and tamoxifen can have direct
effects in isolated mitochondria suggests that speciﬁc intramitochon-
drial mechanisms must exist. Lobaton et al. have demonstrated an
ER-dependent inhibition of the mitochondrial Ca2+ uniporter [216].
Reduced Ca2+ inﬂux would certainly account for an inhibitory effect
of estrogens on permeability transition. As has already been
extensively discussed in this review, mitochondrial ER-dependent
changes in mtDNA transcription and MRC complex formation has
been shown to reduce mitochondrial oxidant production. Alterna-
tively, activation of ER has also been reported to increase MnSOD
activity in mitochondria, independent of changes in protein [217].
Either way a reduction in ROS would decrease the probability of
mitochondrial pore opening. Off-ER estrogen targets may also exist.
For example, tamoxifen may be able to directly affect the ANT [218],
inhibition of which can block mitochondrial permeability transition
[219]. Of course the easiest way for E2 to inhibit the pore would be for
it to bind, either directly or through the ER complex, to components of
the mitochondrial pore. However, until the true components of the
pore are identiﬁed, the existence of such a mechanism remains
untestable. In regard to a role of ERs in the regulation of MPTP, Yang et
al. [220] recently demonstrated that ERβ was mainly localized within
mitochondria of immortal hippocampal cells and primary hippocam-
pal neurons and that knocking down ERβ expression in these cells
resulted in a lower resting mitochondrial membrane potential Wm
and increase in resistance to hydrogen peroxide-induced Wm
depolarization, in association with changes in ATP concentrations
and reduced levels of mitochondrial superoxide in these cells. Similar
mitochondrial phenotype changes were observed in primary hippo-
campal neurons derived from ERβKO mice. These data support the
notion that mitochondrial ERβ functions as a mitochondrial vulner-
ability factor involved in Wm maintenance, potentially through a
mitochondrial transcription dependent mechanism.
In addition to playing a regulatory role in MPTP, ANT is involved in
the mediation of ATP/ADP shuttle cross the mitochondrial membrane,
thereby transporting the majority of MRC-generated ATP out of
mitochondria in exchange of ADP and Pi (Fig. 1). There are several
tissue-speciﬁc isoforms of ANT, namely ANT-1, ANT-2, ANT-3 and ANT-
4. It has been reported that the expression of the heart-speciﬁc ANT
isoform (ANT-1) is enhanced by E2 [221]. Interestingly, the anti-
apoptotic protein, Bcl-2, is an important component of mitochondrial
ANT system and is involved in the regulation of ANT shuttle. Bcl-2 was
shown to enhance ANT-dependent ADP/ATP exchange activity by
direct protein–protein interaction with ANT [222,223]. Its expression
is enhanced by E2 in a number of cells [72,224–229]. It has been
suggested that Bcl-2 family members may regulate important
mitochondrial and cellular functions and serve as sentinels to detect
abnormalities in these pathways and, when the abnormalities are
severe enough, to initiate or facilitate cell death. Understanding the
physiological processes controlled by the Bcl-2 and Bcl-2 family will
be important in understanding cell regulation, and may provide new
insights into the regulation of apoptosis [230].
6.3. E2/ER-mediated mitochondrial effects in the regulation of cell
proliferation and anti-apoptosis
6.3.1. Implications of E2/ER-mediated MRC biogenesis in cell proliferation
E2 stimulates cell proliferation in a number of cells including breast
epithelial cells. MRC plays an important role in the control of cell
proliferation. It is likely that the E2/ER-mediated the MRC biogenesis
has important implications in the regulation of cell proliferation via
generating the large majority of cellular energy in the form of ATP and
ROS. The contribution of theMRC to cell proliferation ismost evidently
based on the several studies on the effects of down- and up-regulation
of MRC protein expression/functions on cell cycle progression and cell
growth.
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to cell cycle arrest and reduced cell growth. Mandal et al. [231]
observed that a mutation in COXVa gene caused a drop in intracellular
ATP to levels sufﬁcient to maintain cell survival, growth, and
differentiation, but not to enable progression through the cell cycle.
Analysis of this gene revealed that a speciﬁc pathway involving AMPK
and p53 was activated that eliminated Cyclin E, resulting in cell cycle
arrest. This study demonstrates that mitochondria have a direct and
speciﬁc role in enforcing a G1-S cell cycle checkpoint during periods of
energy deprivation. Schauen et al. [232] demonstrated that loss of a
functionalMRC by depletion of mtDNA inhibited cell cycle progression
through decreasing ROS levels, leading to down-regulation of
p21CIP1/WAF1. Sustained inhibition of MRC oxidative phosphoryla-
tion (OXPOP) with antimycin A or a partial uncoupling of OXPOP with
uncoupler carbonylcyanide triﬂuoromethoxyphenylhydrazone (FCCP)
impaired cell proliferation and induced premature senescence in
human ﬁbroblasts [233,234]. Treatment of human lung cancer cells
with either antimycin A or 2,4-dinitrophenol, another uncoupler of
OXPOP, prevented the cell growth via inducing apoptosis [176,235].
Over-expression of MRC proteins, on the other hand, has been
found to promote cell proliferation. For example, in a poorly
differentiated, rapidly growing Morris hepatoma 3924A, the mRNA
and protein levels of Tfam are elevated more than 10-fold. The mRNA
levels for COX I, II and ND5 and ND6, the downstream targets of
Tfam, were increased 10-, 8-, 5-, and 3-fold, respectively. The mRNA
levels for NRF-1, NRF-2, were 5- and 3-fold higher, respectively, in the
hepatoma relative to the host liver [90]. Up-regulation of the MRC
proteins and cellular proliferating regulators were seen in thyroid
oncocytomas compared with normal thyroid tissue [236]. In
proliferating cells, transcription and replication of mtDNA is highly
enhanced by parkin, a RING protein located within the mitochondria,
via its association with Tfam [237]. Increased mitochondrial ATP
synthase was seen to be involved in liver metastasis of colorectal
cancer [238].
The contribution of enhancedMRC biogenesis and functions to cell
proliferation can be attributed, in part, to its generation and supply of
energy in the form of ATP and ROS for a number of cellular processes.
The large number of cellular activities, including cell cycle progres-
sion, synthesis of proteins, DNA, RNA, carbohydrates, lipids and other
molecules, active transport across membrane by various ion channels/
transporters, kinase-dependent signaling pathways, are all driven by
ATP. ROS at low to moderate levels serve as the second messenger for
redox regulation of proteins involved in growth-related processes. By
up-regulating the MRC biogenesis and functions, E2 and ERs
contribute, at least in part, to the stimulation of cell growth and
proliferation.
6.3.2. Implications of E2/ER-mediated MRC biogenesis in inhibition of
apoptosis
Apoptosis is a fundamental cellular activity to protect the cells
against neoplastic development by eliminating genetically damaged
cells or those cells that have been improperly induced to divide by
mitotic stimuli. Like a number of tumor promoters [239], E2 normally
inhibits spontaneous and induced-apoptosis in a number of cell types
including human breast cancer cells [225,240,241], brain neurons
[242,243], heart endothelial cells [244,245], skeletal muscle cells
[246], human lens epithelial cells [247], rat hepatocytes [248] and
other cells [249,250]. The mechanisms underlying E2-mediated
inhibition of apoptosis are not clearly understood. Several mechan-
isms/pathways may be involved in these effects, depending on the cell
types. A number of signaling pathways, including mitogen-activated
protein kinase and phosphoinositide 3-kinase signaling that are
mediated by the membrane-associated ERα, are implicated in the
anti-apoptotic effects of E2 in human breast cells, neurons and
cardiomyocytes [240,241,251,252]. The anti-apoptotic effects of E2 in
other cells may be mediated by other events, including induction ofthe expression of baculoviral inhibitors of apoptosis repeat-containing
1 (Birc1) in uterine cells [249]. Apoptosis is triggered by increasing
levels of the MRC-derived ROS induced by a number of anti-cancer
drugs (see Section 7.2 Implications in anti-cancer drug resistance).
Inhibition of ROS-induced apoptosis can be achieved by increasing
mitochondrial anti-oxidants, which detoxify ROS. It has been shown
that E2 activated the mitochondrial ERα to increased mitochondrial
Mn-superoxide dismutase (MnSOD) activity, which is involved in
inhibition of UV-induced apoptosis in MCF-7 cells [54,253]. It has also
been reported that MnSOD activity was activated by E2 in mitochon-
dria of cerebral vessels of rat brain [67] and human lens epithelial cells
[217] (for more details see Section 7.5 Implications in beneﬁcial effects
of estrogens/ERs on lens physiology). In addition, E2 treatment of rat
hepatocytes caused increased mitochondrial distribution of glu-
tathione (GSH), another major mitochondrial anti-oxidant [72]. The
increased mitochondrial MnSOD activity and GSH levels within
mitochondria can detoxify ROS. Furthermore, it has been known
that estrogens up-regulate the expression of the anti-apoptotic
proteins, e.g. Bcl-2 [72,225,254,255]. The combination of these effects
may partially account for E2's anti-apoptotic effects.
In addition, E2/ER-mediated MRC biogenesis/functions may con-
tribute to E2-mediated inhibition of apoptosis. It has shown that the
inhibition of TFGβ-induced apoptosis by EE in rat hepatocytes was
accompanied by EE induction of transcript levels of MRC proteins and
ATP levels [72,248]. ERβ has been known to play a major role in
mediating E2's beneﬁcial effects on cardiac function following
trauma–hemorrhage (T–H). Treatment of male rats that underwent
T–H with E2 or DPN (an ERβ-selective agonist) enhanced the
expressions and activity of complex IV and ATP production. These
effects were blocked by co-treatment with complex IV speciﬁc
inhibitor. Importantly, these effects are required for inhibition of
mitochondrial apoptotic signaling pathways [76]. Estrogens may up-
regulate the expression of human ATP-dependent RNA and DNA
helicase (SUV3) that is involved in mtDNA replication because the
promoter of this gene contains NRF-1, Sp1 and NF-B binding sites.
Interestingly, this protein has been found to be associated with HBXIP
that was identiﬁed as a cofactor of survivin in suppression of
apoptosis. The HBXIP binding domain is important for mitochondrial
import and stability of the Suv3 protein in vivo [102,256].
The genetic and pharmacological studies described in Section 6.1
Evidence for the MRC as an important regulator of apoptosis indicate
that up- or down-regulation of the MRC biogenesis/functions may
determine the fate of cell death via apoptosis or cell survival by
inhibition of apoptosis. Thus, a persistent stimulation of MRC
biogenesis/functions by E2 and ERs should contribute to inhibition
of apoptosis, causing the normal balance of cell growth/cell death
toward survival and enhanced cell growth. Inhibition of apoptosis is
one of important mechanisms of carcinogenesis.
7. Physiological and pathological implications
The MRC is crucial to the large majority of cellular functions. The
regulation of the MRC biogenesis and functions by E2/ERs confers a
large number of physiological effects. The fact that E2 and ERs
stimulate MRC biogenesis and functions in such organs/tissues as
breast, brain, heart, and eyes that have high demand for energy supply
for their proper functions reﬂects the physiological importance of
these effects. MRC-derived ROS also play important roles in the
regulation of a number of cellular functions. However, an over-
abundance and/or deﬁciency of these E2/ER-mediated mitochondrial
effects could lead to pathological consequences and diseases,
depending on the types and age of the target cells and tissues. The
energy demand, availability/levels of E2 and ER isoforms, subcellular
localization of ERs and the duration of their actions, and the
vulnerability of the cells to ROS stress will determine the physiological
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7.1. Implications in estrogen carcinogenesis in breast cancer cells
Breast cancer is the second leading cause of cancer-related death
among women in U.S. and other developed countries. Prolonged
exposure to excess E2 is a key etiological factor for the development of
breast cancer. Because human breast cells are exposed to relatively
high levels of E2 due to the in situ E2 synthesis by local aromatase
activity [257,258] and estrogen replacement therapy, their growth and
development are under persistent control by E2. The carcinogenic
effects of E2 are mediated via ERα- and ERβ-mediated genomic
pathways and by the genotoxic effects caused by oxidative estrogen
metabolites [259]. As described above, over-abundance of E2/ER-
mediated MRC biogenesis and functions may contribute to the
stimulation of cell proliferation and inhibition of apoptosis. It is likely
that the persistent stimulation of theMRC biogenesis and functions by
E2 and ERs exists in breast cells, which can lead to alterations in energy
metabolism, abnormal cell growth and inhibition of apoptosis in
breast cells. All of these may contribute to estrogen carcinogenesis of
breast cancer. The potential implications and relevance of E2/ER-
mediated effects on mitochondria to estrogen carcinogenesis have
been described elsewhere [46,113]. Several lines of new evidence are
presented here to further support this notion. First, altered mitochon-
drial functions are becoming crucial to understanding cancer
mechanisms. For example, Putignani et al. [260] observed distinct
differences in mitochondrial proteins between normal and breast-
inﬁltrating ductal carcinoma (IDC) cells. They detected depressed
expression levels for all MRC complexes in human mammary
carcinoma, particularly for NDUFS3 (complex I), SDHB subunits
(complex II), 2 UQCRC2 (complex III), COX 1 (complex IV) and ATPβ
(complex V). These changes were associated with reduction in COX
and ATP synthase activity, deterioration in mitochondria morphology
and changes in mitochondria membrane. These data described
bioenergetic and phenotypic alterations of IDC cell mitochondria.
Similarly, Abril et al. [261] detected altered expression of 12S/RNR1,
COX1/COX2 (complex IV), and ATP6 (complex V) in prostate cancer
cells. Furthermore, a proteomic analysis of brain metastasis of human
breast cancer cells [262] revealed increased expression of proteins
involved in several energy metabolism pathways including glycolysis,
tricarboxylic acid cycle, oxidative phosphorylation, the pentose
phosphate pathway and the glutathione system. These metabolic
alterations were associated with strongly enhanced tumor cell
survival and proliferation in the brain microenvironment. Second,
other carcinogens can cause alterations in mitochondrial functions.
For example, the carcinogenic polycyclic aromatic hydrocarbon DNA
adducts caused multiple alterations in gene expression. A proteomic
analysis revealed altered expression of several MRC proteins of MCF-7
cells treated with benzo[a]pyrene [263]. Third, persistently enhanced
generation of MRC-derived ROS induced by E2/ERs may cause
progressive oxidative damage to mtDNA and mitochondrial proteins,
leading to mutations in mtDNA and malfunction of MRC. Indeed,
several types of mtDNAmutations have been detected in breast cancer
tissue and in matched nipple aspirate ﬂuid [264–266]. It has been
shown that mitochondrial genetic background modiﬁed breast cancer
risk [267,268].
In addition, altered MRC functions could lead to retrograde
regulation that has been implicated in carcinogenesis [269]. Mito-
chondrial retrograde signaling is a pathway of communication from
mitochondria to the nucleus that inﬂuences many cellular and
organismal activities under both normal and pathological conditions
[269–271]. This signaling pathway is triggered by mitochondrial
dysfunction and is not a simple on-off switch, but rather it responds in
a continuous manner to the changing metabolic needs of the cell.
Communication between mitochondria and the nucleus is importantfor a variety of cellular processes such as carbohydrate and nitrogen
metabolism, cell cycle and proliferation, cell growth and morphogen-
esis [269]. By altering the levels of MRC-derived ATP, ROS and other
intermediate metabolites, E2/ER-mediated MRC biogenesis and func-
tions can trigger mitochondrial retrograde signaling. For example, it
has been shown [73,272,273] that the E2-mediated MRC-derived ROS
are involved in the regulation of the nuclear redox-sensor kinases, e.g.
A-Raf, Akt and PKC, which in turn, activate transcription factors NF-B,
CREB, AP-1 via MEK/ERK pathways, that are involved in cell growth.
Depletion of mtDNA has been shown to cause mitochondrial
impairment in breast cancer cells, leading to altered expression of
nuclear genes involved in signaling, cellular architecture, metabolism,
cell growth/differentiation, and apoptosis [274]. Proteomic analysis of
mitochondria-to-nucleus retrograde response in human cancer
identiﬁed quantitative changes in expression of several proteins
including subunits of complex I and complex III, molecular chaper-
ones, and a protein involved in cell cycle control were down-regulated
and inosine 5′-monophosphate dehydrogenase type 2 (IMPDH2)
involved in nucleotide biosynthesis was up-regulated in mtDNA-
depleted rho (0) cells, suggesting that these proteins play key roles in
retrograde response. Interestingly, further analysis of expression of
UQCRC1 gene (encoding ubiquinol cytochrome c reductase core
protein I) in breast and ovarian tumors revealed that UQCRC1 was
highly expressed in breast (74%) and ovarian tumors (34%) and that its
expression positively correlated with mtDNA-encoded COXII [275].
7.2. Implications in anti-cancer drug resistance
Themajority of anti-cancer drugs confer their anti-cancer activities
by inducing apoptosis and/or inhibiting cell growth and proliferation.
Cancer cells acquire drug resistance as a result of selection pressure
dictated by unfavorable microenvironments. This survival process is
facilitated through efﬁcient control of oxidative stress originating
from mitochondria that typically initiates apoptosis. Several anti-
cancer drugs have been shown to targetMRC and alterMRC biogenesis
and functions. Alterations in MRC protein expression/functions are
frequently seen in a number of cancer cells that are resistant to anti-
cancer drugs.
7.2.1. Implications in tamoxifen resistance in breast cancer cells
Tamoxifen (TAM), an ER antagonist that blocks E2-mediated cell
growth and provokes apoptosis, is widely used for treatment of ER-
positive breast cancer patients. TAM and its metabolite, 4-hydro-
xytamoxifen (4-OH-TAM), can induce apoptosis through both ER-
dependent and ER-independent pathways [276]. Several lines of
evidence have indicated that MRC are important targets of TAM via
ER-dependent and ER-independent pathways.
TAM has acute inhibitory effects on oxidative phosphorylation in
isolated rat liver mitochondria [209,218,277,278]. It has been observed
[279] that treatment of TAM-sensitive MCF-7 and MAB-MB-231 cells
with TAM induced apoptosis and that these effects were inhibited by
bongkrekic acid, an inhibitor of MPT. The pure anti-estrogen ICI
182780 partly inhibited the effect of TAM in ER-positive MCF-7 cells,
but not in ERα-negative MDA-MB-231 cells. Pre-culturing MCF-7 cells
in the absence of E2 or in the presence of a low TAM concentration
made the cells even more susceptible to rapid death induced by TAM.
These results suggest that disruption of mitochondrial function has a
primary role in the acute death response of the cells and that E2 via
ERs has protective effects on mitochondrial functions. Moreira et al.
[280] demonstrated that TAM interacted with the ﬂavin mononucleo-
tide site of complex I, leading to mitochondrial failure. Ridaifen-B, a
novel TAM derivative, has been shown to induce apoptosis in ER-
negative breast cancer cells by reducing mitochondrial membrane
potential [281]. Pancratistatin (PST), a natural compound obtained
from the Hawaiian spider lily, has been known to be speciﬁc and
selective in inducing apoptosis in multiple cancer cell lines. It targets
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ROS, decreased ATP and mitochondrial membrane permeabilization
[282]. When combined with TAM, PST caused synergic effects on
breast cancer cells in inducing apoptosis by targeting mitochondria
[283]. In addition, TAM has been shown to indirectly inﬂuence MRC
functions via increasing intramitochondrial ionized Ca(2+) levels and
stimulating mitochondrial NO synthase (mtNOS) activity in MCF-7
cells. By stimulating mtNOS, TAM hampered mitochondrial respira-
tion, releases cytochrome c, elevates mitochondrial lipid peroxidation,
increased protein tyrosine nitration of certain mitochondrial proteins,
decreased activity of succinyl-CoA:3-oxoacid CoA-transferase, and
induced mitochondrial aggregation [284].
A major clinical problem for TAM therapy is that a high percentage
of breast cancer patients ultimately become TAM resistant (TAM-R).
While the mechanisms underlying TAM-R are not completely under-
stood, altered MRC protein expression and deregulation of MRC
functions, which have been observed in TAM-R cells, may be a
contributing factor. It has been reported [285] that TAM induced
apoptosis in normal human mammary epithelial cells (HMECs) that
have lost the tumor suppressor p53 function (p53−). However, these
cells rapidly developed resistance toTAM-induced apoptosis within 10
passages in vitro. Resistance to TAM in late passages of p53−/− HMEC-
E6 cells correlated with an increase in mitochondrial mass, a lack of
mitochondrial depolarization and caspase activation following TAM
treatment, suggesting altered mitochondrial functions in TAM-R cells.
Indeed, a proteomic comparison of TAM-S versus TAM-R xenografted
human breast cancer revealed an enhanced expression of MRC
proteins in association with altered expression of proteins involved
in cell–cell adhesion/interaction, signal transduction, DNA and protein
synthesis machinery, oxidative stress processes and apoptosis [286].
Similar alterations in the mitochondrial proteome were also detected
in adriamycin resistant MCF-7 cells [287].
7.2.2. Implications in other anti-cancer drug resistance
Alterations in MRC protein expression and MRC activities are also
observed in other cancer cells resistant to several widely used anti-
cancer drugs, including 5-luorouracil (5-FU), cisplatin and docetaxel.
5-FU is the mainstay of chemotherapy for the treatment of
patients with advanced colon cancers. However, the acquisition of
resistance to 5-FU is a prominent obstacle to successful chemother-
apy. Several studies reported altered expression of MRC proteins, ATP
synthase and proteins involved in MRC protein synthesis in 5-FU-
resistant cells. For example, Tanaka et al. [288] identiﬁed enhanced
levels of Tfam in association with a heterogeneous nuclear ribonu-
cleoprotein G histone H2B, histone H4 and ribosomal protein L3 in 5-
FU-resistant cells. These proteins are potentially related to 5-FU
resistance by protecting the cells from mtDNA and nDNA damage.
Shin et al. [289] detected lower levels of the ATPα subunit and ATP
synthase d-subunit, reduced ATP synthase activity and ATP contents
in 5-FU-resistant cells compared with parent cells. Furthermore,
suppression of ATP synthase d-subunit expression by siRNA increased
cell viability in the presence of 5-FU. Down-regulation of ATP
synthase β-subunit expression was also seen in breast, liver, kidney,
colon, squamous oesophageal, and lung carcinomas and gastric
adenocarcinomas, suggesting that ATP synthase down-regulation
may lead to cellular events responsible for 5-FU resistance.
Cisplatin is a platinum drug used as a cornerstone of current
chemotherapy regimens. Development of resistance to this drug by
tumors signiﬁcantly decreases its usefulness in the clinic. It has been
reported that the expression of SIRT1, which belongs to the family of
type III histone deacetylase and is implicated in diverse cellular
processes, wasmarkedly up-regulated in androgen-refractory PC3 and
DU145 cells compared with androgen-sensitive LNCaP cells and that
its expression level was correlated with cell growth in PC3 cells.
Treatment with a SIRT1 inhibitor, sirtinol, inhibited cell growth and
increased sensitivity to cisplatin. Silence of SIRT1 expression by siRNAalso suppressed cell proliferation and reduced resistance in PC3 cells,
mimicking the effect caused by sirtinol. Also in DU145 cells, sirtinol
treatment enhanced sensitivity to cisplatin [290]. SIRT1 contributes in
part to cisplatin resistance by reducing glucose use and altering
mitochondrial metabolism [291]. Qian et al. [292] observed that
mitochondrial density in intestinal epithelium determined the cellular
sensitivity to cisplatin-induced cell death.
Docetaxel is an effective chemotherapeutic agent against cancer
but some patients develop resistance. It has been found [293] that
docetaxel-resistant DRHEp2 cells developed from human laryngeal
cancer HEp2 cells had greatly increased mtDNA content whereas
reduction of mtDNA content in DRHEp2 cells by ethidium bromide
treatment reduced the resistance, suggesting a role for mtDNA-coded
MRC proteins in resistant mechanisms. Oligomycin A (a F0–F1 ATPase
inhibitor) but not inhibitors of other MRC complexes eliminated
docetaxel resistance in these cells, indicating a role for mtDNA-coded
ATPase subunits in resistant mechanisms. Docetaxel induced ROS
generation in HEp2 cells but not in DRHEp2 cells. Anti-oxidant
pyrrolidine dithiocarbamate eliminated docetaxel-induced cytotoxi-
city. Furthermore, inhibition of F0–F1 ATPase by oligomycin A induced
docetaxel-mediated ROS generation in DRHEp2 cells. Taken together,
DRHEp2 cells acquired docetaxel resistance through increasing F0-
ATPase, which diminished docetaxel-induced ROS generation and
subsequent inhibition of cell death. The mtDNA plays an important
role in development of docetaxel resistance through the reduction of
ROS generation by regulating F0-ATPase [293].
Persistent alterations of MRC biogenesis and functions induced by
E2 and ERs may cause changes in the responsiveness of cells to anti-
cancer drugs that target mitochondria. Thus, regulation of E2/ER-
mediated mitochondrial pathway may represent a promising way to
overcoming anti-cancer drug resistance.
7.3. Implications in neuroprotective effects
The human brain is only 2% of the body weight, but it consumes
about 20% of the total energy in the body at rest. The human brain is
the most energy hungry organ in the body thereby increasing its
vulnerability. Sufﬁcient supply of mitochondrially-derived energy is
essential for the proper functions of the brain. It has been known that
if the energy supply is cut off for 10 min, there is permanent brain
damage. No other organs are as sensitive as brain in response to the
changes in its energy supply. Defective mitochondrial structure and
MRC dysfunctions have been observed in patients with neurodegen-
erative diseases such as Alzheimer's diseases (AD) and Parkinson's
disease (PD) [294–297]. Epidemiological studies have indicated that
estrogen therapy reduced the risk of developing AD and PD in
women. Clinical and experimental studies have shown that estrogens
are potent modulators of the brain's functions and have beneﬁcial
effects in mental and neurodegenerative diseases. For example, Xu
et al. [298] observed signiﬁcant alterations in mitochondrial
ultrastructure and signiﬁcant reduction in ATP levels in hippocam-
pal neurons of Ovx rats. These alterations caused by Ovx were
reversed by treatment with estrogen and phytoestrogens (e.g.
genistein and ipriﬂavone), revealing a critical role of estrogens in
preservation of mitochondrial structure and functions in brain
neurons. Consistent with this observation, a transient alteration of
COX activity and mitochondrial ATP content in hippocampi of young
Ovx rats and a prolonged lowering of COX activity and mitochon-
drial ATP content were seen in hippocampi of middle-aged Ovx
rats. Furthermore, treatment of these rats with estradiol benzoate
(EB) or genistein reversed this estrogen withdrawal-induced
mitochondrial dysfunction in both young and middle-aged rats
[299,300]. The general effects of estrogens on several aspects of
mitochondrial functions of brain neurons in relation to estrogen's
neuroprotection on neurodegenerative diseases have been described
elsewhere [301–305]. The potential implications of E2/ER-mediated
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described as the follows.
7.3.1. Implications in neuroprotection in Alzheimer's disease
Alzheimer's disease (AD) is by far the most common neurodegen-
erative dementia among the elderly. Patients with AD initially show
memory loss, and as the disease progresses they develop impaired
executive function, confusion and personality change and eventually
death [306]. The incidence of AD is lower in young women than in
men but is increased among post-menopausal women. These
observations indicate that estrogens have important protective effects
against the development of AD.
There are several pathological hallmarks for AD. One of which is
the abnormal aggregation of a protein called Tau, a microtubule-
associated protein, within nerve cells. The Tau-bearing lesions appear
initially in the entorhinal cortex and hippocampus, then progress to
neocortex of the frontal and temporal poles, and ﬁnally involve much
of the temporal, frontal, and parietal cortices. Tau associates with
microtubules to form Tau aggregation, which appears as neuroﬁbril-
lary tangles, neuritic plaques, and neuronal threads. Nerve cells in
which Tau protein aggregated could not grow and function properly
[307]. Tau is closely related tomitochondrial function. Transgenicmice
over-expressing the P301L mutant human tau protein exhibited an
accumulation of hyperphosphorylated Tau and develop neuroﬁbril-
lary tangles. Proteomic and functional analyses [308] revealed a
mitochondrial dysfunction in P301L tau transgenic mice. Signiﬁcantly,
the reduction in MRC complex V levels, COX I activity and, with age,
impaired mitochondrial respiration and ATP synthesis were observed
in the P301L tau mutant mice. Mitochondrial dysfunctions were
associated with high levels of ROS in aged transgenic mice. Increased
Tau pathology seen in aged homozygous P301L Tau mice was
accompanied by modiﬁed lipid peroxidation levels and up-regulation
of anti-oxidant enzymes in response to oxidative stress. A recent study
[309] revealed that a peptide containing residues 26–44 of Tau protein
targeted COX and ANT and impaired MRC oxidative phosphorylation
at the level of ANT, conferring deleterious effects on cellular
availability of mitochondrial ATP.
The second important hallmark of AD is the amyloid plaques
comprised of the amyloid Abeta peptides, which cause toxic effects on
nerve cells by inducing mitochondrial dysfunction, including altered
calcium homeostasis and Bcl-2 expression, associated with increased
neuronal apoptosis [310]. It has been shown that soluble beta-amyloid
caused mitochondrial defects in amyloid precursor protein and Tau
transgenic mice as evidenced by mitochondrial damage such as
reduced mitochondrial membrane potential and ATP levels in the
brains from these mice before the onset of plaques [311]. A study [312]
reported that the amyloid beta-peptide was imported into mitochon-
dria via the Tom import machinery and localized to mitochondrial
cristae. Both oligomeric and ﬁbrillar species but not a disaggregated
(mainly monomeric) form of Abeta42 have been also shown to impair
mitochondrial function in P301L Tau transgenic mice. Aging speciﬁ-
cally increased the sensitivity of mitochondria to oligomeric Abeta42
damage [313]. The amyloid peptide exposure provoked down-
regulation of a key anti-apoptotic protein, Bcl-2, and resulted in
mitochondrial translocation of Bax, a protein known to promote cell
death, and increasesmitochondrial peroxide production, nitration and
oxidation of proteins and subsequent release of cytochrome c [310].
Mitochondrial dysfunction has been identiﬁed in AD [306]. Since
both Tau and Abeta act on mitochondria, there could be a synergistic
action of Tau and Abeta on the mitochondria. Indeed, P301L tau
mitochondria displayed increased vulnerability toward Abeta peptide
insult. There may be direct impact of abnormally phosphorylated tau
and Abeta on proteins/enzymes involved inmetabolism,MRC function
and cellular detoxiﬁcation [314]. However, Tau pathology involves a
mitochondrial and oxidative stress disorder which may be distinct
from that caused by Abeta.E2 has been shown to be neuro-protective in a number of animal
models of AD. It has multi-functional effects, causing a reduction in
the development of AP by preventing or reducing the Tau aggregation
and formation of amyloid plaques
Abnormal Tau hyperphosphorylation by protein kinases such as
protein kinase A (PKA) plays an important role in PD pathogenesis
[315]. It has been reported [316] that E2 effectively attenuated
forskolin-induced over-activation of PKA and elevation of cAMP, and
thus prevented Tau from hyperphosphorylation. Serine/threonine
protein phosphatases (PP) such as protein phosphatases PP1, PP2A,
and calcineurin are involved in hyperphosphorylation of Tau [317].
Using speciﬁc inhibitors for PP1, PP2A and calcineurin, Yi and
Simpkins [317] have demonstrated that these proteins played a role
in estrogen-mediated neuroprotection. Zhang et al. [318] revealed a
role of Dickkopf-1 (Dkk1) in the attenuation of Tau phosphorylation
and E2-induced neuroprotection. DKK1 is an antagonist of the Wnt/
beta-catenin signaling pathway. This pathway is a principal mediator
of neurodegeneration in cerebral ischemia and AD. E2 at low
physiological levels protected the hippocampus CA1 against global
cerebral ischemia by preventing Dkk1 elevation. This effect correlated
with a reduction of phospho-beta-catenin and elevation of nuclear
beta-catenin levels. E2 inhibition of Dkk1 is a critical mechanism
underlying its neuro-protective and phospho-tau regulatory effects
after cerebral ischemia. Thus, hyperphosphorylation of Tau could be a
promising therapeutic target for AD [315].
In addition to attenuating Tau hyperphosphorylation, E2 has
preventive effects against amyloid beta-mediated neurotoxicity. E2
exposure prior to neurotoxic insult of hippocampal neurons promoted
neuronal defense and survival against amyloid beta. It has been
observed [310] that treatment of cultured rat hippocampal neurons
with E2 prior to amyloid beta exposure signiﬁcantly reduced the
number of apoptotic neurons and the associated rise in resting
intracellular calcium levels. E2 pre-treatment inhibited the amyloid
beta-induced apoptosis. These anti-apoptotic effects of E2 could be
attributed to: 1) activation of anti-oxidant defense systems scaven-
ging ROS and limiting mitochondrial protein damage [303]. It was
observed that E2 induced expression of anti-oxidative and anti-
apoptotic thioredoxin (Trx) and MnSOD expression following the
induction of NOS1 in human brain-derived SH-SY5Y cells [319]; and 2)
improvement of MRC electron transport chain activity and reducing
mitochondrial DNA damage as well as increasing the activity of
complex IV of the electron transport chain, improving mitochondrial
respiration and ATP production under normal and stressful conditions.
In fact, E2 treatment enhanced the expression of genes encoding MRC
proteins in rat hippocampus [70] and pituitary tumor cells [71]. In vivo
treatment of rats with E2 up-regulated brain mitochondrial proteome,
COX IV activity and MRC functions[75,77].
Inhibition of the assembly of amyloid beta-peptide and the
destabilization of preformed beta-amyloid ﬁbrils (fAbeta), prevention
and/or inhibition of Tau hyperphosphorylation in the central nervous
system could represent a valuable therapeutic approach for patients
with AD. Estrogen has anti-amyloidogenic effects on Alzheimer's
fAbeta in vitro [320]. E2 also attenuates Tau hyperphosphorylation. On
the other hand, the stimulation of theMRC biogenesis and functions in
neurons of brain by E2/ERs offsets the damage on mitochondrial
functions caused by Tau and fAbeta and thus, are implicated in
protection against AD.
Based on the pathological features of AD, it was proposed [321]
that drug discovery for AD should include: (i) supplementation
therapy, (ii) anti-apoptotic compounds, (iii) substances with a
mitochondrial impact, (iv) anti-amyloid substances, (v) anti-protein
aggregation and (vi) lipid-lowering drugs. Estrogen replacement
therapy for AD appears to fully ﬁll (ii), (iii), (iv) and (v). However,
because of the potential carcinogenic effects of E2 in breast cancer
(Section 7.1 Implications in estrogen carcinogenesis in breast cancer
cells) and the highly oxidative cellular environment present in brain
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neurodegeneration, E2 itself is a poor agent for treatment of existing
AD [303]. In this regard, in cultured cells and animal models of AD,
other estrogenic chemicals, some with less hormonal effects, have
been shown to be neuro-protective, including 17α-estradiol
[322–324], selective agonists for ERα(PPT) and ERβ (DPN) [229],
phytoestrogens [325,326], and a hybrid structure of E2 and vitamin
E [327].
7.3.2. Implications in neuroprotective effects against Parkinson's disease
Parkinson's disease (PD), the second most common neurodegen-
erative disorder, is characterized by the degeneration of dopaminergic
neurons in the substantia nigra. Themost vulnerable neurons reside in
the substantia nigra zona compacta (SNC), whereas the DA neurons in
the ventral tegmental area (VTA) and interfascicular (IF) nucleus are
less vulnerable to degeneration (for review see [328]). There are two
forms of PD, the rare familial form and the more common sporadic
form. Both familial and sporadic PD patients have defects in
mitochondrial respiration. Exposure to environmental mitochondrial
toxins leads to PD-like pathology.
PD is more frequent in men than in women, and is more prevalent
inwomenwith short reproductive life [329]. Estrogens are considered
neurotrophic for dopamine neurons and are neuro-protective against
neurotoxic agents for dopamine neurons in vivo and in vitro[330]. The
neuroprotection of E2/ERs on PD could be attributed, in part, to their
effects on MRC biogenesis/functions and its potential effects on PD-
related proteins that are involved in the control of mitochondrial
functions. Several mitochondrial proteins including PTEN-induced
kinase 1(PINK1), Parkin, DJ1, α-synuclein and POLG are known to be
involved in mediation of both familial and sporadic forms of PD.
Recent studies on these genes have revealed the central importance of
mitochondrial dysfunction and oxidative stress in both forms of PD
[328,331–333].
Pink1 is a putative serine/threonine kinase localized in mitochon-
dria. It is highly conserved from Drosophila to human. It has been
shown that removal of Drosophila Pink1 homologue function resulted
in defects in mitochondrial morphology (e.g. fragmented mitochon-
drial cristae). These effects were associated with male sterility,
apoptotic muscle degeneration, and increased sensitivity to multiple
stresses including oxidative stress whereas expression of human
Pink1 in the Drosophila restored these defects in a portion of pink1
mutants [331]. It has been reported [334] that the germline deletion of
the Pink1 gene in mice signiﬁcantly impaired mitochondrial functions
in the striatum but not in the cerebral cortex at 3–4 months of age.
Decreased MRC activities in the cerebral cortex were evident in
Pink1(−/−) mice at 2 years, indicating that aging can exacerbate MRC
dysfunction in these mice. Moreover, MRC defects were induced in
the cerebral cortex of Pink1(−/−) mice by cellular stress. Mitochon-
drial aconitase activity associated with the Krebs cycle was also
reduced in the striatum of Pink1(−/−) mice. Because mitochondrial
aconitase contains an iron–sulfur core that is oxidized by ROS, the
activity of this enzyme is a useful ﬁngerprint of mitochondrial ROS.
The reduced activity of this enzyme in the striatum of Pink1(−/−)
mice reﬂects an increased mitochondrial ROS, indicating a key role of
Pink1 in the regulation of oxidative stress. Furthermore, mutations in
human Pink1 caused hereditary early onset of PD [335]. Together,
these ﬁndings demonstrate an important role of mammalian Pink1
for mitochondrial function, which provides critical protection against
both intrinsic and environmental stress. Thus, loss of Pink1 may lead
to nigrostriatal degeneration in PD.
Parkin is a ring protein located in the outer mitochondrial
membrane of proliferating cells and is involved in mitochondrial
biogenesis. Parkin is functionally linked to Pink1 in that its
mitochondrial translocation is controlled by pink1 kinase activity
through direct phosphorylation in its ring region [336]. Interestingly,
loss of Drosophila parkin showed phenotypes similar to those causedby the loss of pink1 function. Over-expression of parkin rescued the
male sterility and mitochondrial morphology defects of pink1
mutants, whereas double mutants removing both pink1 and parkin
function showed muscle phenotypes identical to those observed in
eithermutant alone. These observations suggest that pink1 and parkin
function, at least in part, in the same pathway, with pink1 functioning
upstream of parkin. The role of the pink1–parkin pathway in the
regulation of mitochondrial function underscores the importance of
mitochondrial dysfunction as a central mechanism of PD pathogen-
esis. In proliferating cells, transcription and replication of mtDNA are
enhanced by parkin over-expression and attenuated by parkin
suppression with siRNA. Parkin is associated with Tfam, enhancing
Tfam-mediated mtDNA transcription. These results indicate that
parkin is involved in the regulation of mitochondrial transcription/
replication in these cells [237,337]. It has been shown [237,337] that
wild-type parkin attenuated ROS production whereas mutant parkin
enhanced ROS production in SH-SY5Y and L6 cells and that over-
expression of parkin reduced ROS. Parkin prevented apoptosis and
enhanced mitochondrial membrane potential in SH-SY5Y and L6 cells
but not in COS-1 cells. Expressions and enzymatic activity of MRC
complex I but not other MRC complexes were selectively enhanced by
Parkin. These results suggest that parkin possesses anti-apoptotic
function in neuronal cells.
DJ-1 has a role in protection against oxidative stress, but its direct
role in mitochondrial function has not been fully established.
Mutations (e.g. homozygous L166P missense mutation) have been
identiﬁed in DJ-1 gene that cause autosomal recessive early onset of
PD. It has been observed [338] that the L166P mutation markedly
reduced stability to DJ-1 protein in vivo, resulting from enhanced
degradation by the proteasome and that the L166P mutant protein
exhibited an impaired ability to self-interact to form homo-oligomers.
Wild-type DJ-1 protein existed in a homo-dimeric form in vitro,
whereas the L166P mutant existed only as a monomer and speciﬁcally
but differentially associated with parkin. These mutants exhibited
impairments in homo-dimer formation, suggesting that parkin may
bind to monomeric DJ-1. Parkin failed to speciﬁcally ubiquitinate and
enhance the degradation of L166P and M26I mutant DJ-1 protein, but
instead promoted their stability in cultured cells [339]. The interaction
between parkin and L166P DJ-1 may involve a larger protein complex
that contains CHIP and Hsp70, perhaps accounting for the lack of
parkin-mediated ubiquitination. Oxidative stress also promoted an
interaction between DJ-1 and parkin, but this did not result in the
ubiquitination or degradation of DJ-1. Parkin-mediated alterations in
DJ-1 protein stability may be pathogenically relevant as DJ-1 levels
were dramatically increased in the detergent-insoluble fraction from
sporadic PD/DLB brains, but were reduced in the insoluble fraction
from parkin-linked autosomal recessive juvenile-onset PD brains.
The α-synuclein is an abundant protein found particularly in
axonal termini and a component of Lewy bodies, a pathological
hallmark of PD. It contains an amino-terminal mitochondrial targeting
sequence and is imported into mitochondria induced by acidiﬁcation
of the cytosol or by its over-expression. The import and accumulation
of α-synuclein has been shown to impair complex I in human
dopaminergic neuronal cultures and PD brain [340]. Defective MRC
function or inhibition of MRC with speciﬁc MRC inhibitors led to
formation ofα-synuclein aggregates in cells associatedwith reduction
in ATP levels [341]. Exposure of human embryonic kidney cells over-
expressing α-synuclein to rotenone caused increased susceptibility to
cell death and lower levels of ATP than control cells. The brainstem
neurons of mice that over-expressed the human Ala53Thr form of α-
synuclein contained degenerating and dysmorphic mitochondria. The
α-synuclein protein also induced oxidative damage and cytochrome c
release. Mice with a knockout of the Snca gene exhibited increased
resistance to MPTP through modulation of complex I activity, whereas
administration ofMPTP tomice that over-expressedα-synuclein led to
swollen, morphologically abnormal mitochondria. These observations
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The data described above indicate a potential link among Pink1,
parkin, DJ-1 and α-synuclein in a common molecular pathway at
multiple levels with parkin and α-synuclein being directly involved in
the regulation of MRC functions. Understanding the regulation of this
Pink1–parkin–DJ-1–α-synuclein pathway may have important impli-
cations for understanding the pathogenesis of inherited and sporadic
PD. A few studies have suggested that Pink1 [342], parkin [330] and
synucleins [343,344] participate in estrogen response pathways. Thus,
E2 and ERs may be involved in the regulation of Pink1–parkin–DJ-
1–α-synuclein pathway in neurons. It is likely that the regulation of
Pink1–parkin–DJ-1–α-synuclein pathway and MRC biogenesis and
functions in neurons by E2 and ERs confer protection for mitochon-
drial functions, protecting neurons from apoptosis induced by ROS
and mitochondrial toxins. A deﬁciency in these E2/ER-mediated
mitochondrial effects may be causally related to pathogenesis of PD.
7.4. Implications in cardiovascular protective effects
Cardiovascular diseases (CVDs) are the major cause of morbidity
and mortality among both men and women. There is a signiﬁcant
gender difference in incidence of CVDs (e.g. atherosclerotic diseases),
in part because of differences in risk factors and hormones [345]. The
incidence of CVDs is uncommon in pre-menopausal women, sharply
rises in post-menopausal women, and is reduced to pre-menopausal
levels in post-menopausal women who receive estrogen therapy,
suggesting that estrogens confer protective effects on the cardiovas-
cular system [346,347].
E2 has both indirect and direct effects on the cardiovascular
system. The indirect effects of E2 include its inﬂuences on serum
lipoprotein and triglyceride proﬁles, and the expression of coagulant
and ﬁbrinolytic proteins. The direct effects of estrogen occur through
both rapid non-genomic and longer-term genomic pathways that are
mediated by the ERα and ERβ. The rapid effects of estrogen result in
the activation of endothelial nitric oxide synthase, leading to arterial
vasodilation, whereas longer-term effects involve changes in gene and
protein expression, modulating the response to injury and athero-
sclerosis [346]. It has been shown [348] that the protective effects of E2
against vascular injury are mediated via ERα.
Mitochondria in the adult mammalian heart have a tremendous
capacity for oxidative metabolism, and the conversion of energy by
these pathways is critical for proper cardiac function [349]. Several
inherited and acquired disorders of mitochondria including defects in
MRC proteins, disruption of oxidative phosphorylation and increased
ROS oxidative stress, lead to defects in cardiac functions as reﬂected in
exercise intolerance, arrhythmias, dilated cardiomyopathy and heart
failure [349–353]. Myocardial ischemia–reperfusion injury also causes
mitochondrial dysfunctions, resulting in low ATP levels, malfunctional
ion pumps/altered ion homeostasis, ruptured plasma membrane and
cell death [186]. These observations suggest that alterations in cardiac
mitochondrial structure and functions play a central role in the
development of the overt heart failure and heart diseases [354].
Recent studies examining the effects of estrogen on mitochondria
of vascular systems have revealed a new paradigm for estrogen's
vascular protection, i.e. the effects of E2/ER on cardiac mitochondrial
structure and function contribute, at least in part, to the E2's cardiac
protective effects [355]. E2 has been shown to profoundly affect
mitochondrial functions in cerebral blood vessels of rat brain,
enhancing efﬁciency of energy production and suppressing mito-
chondrial oxidative stress by up-regulating a number of genes
encoding MRC proteins and anti-oxidant enzymes such as MnSOD
[217,355,356]. E2/ERβ pathways mediate down-regulation of genes
for nDNA-encoded subunits of all MRC complexes whereas ERα is
essential for most of the estrogen-mediated increase in gene
expression including MRC proteins and proteins involved in defenseagainst oxidative stress in wild-type rat aortas [116]. In contrast,
Hsieh et al. [76] observed up-regulation of the expression and activity
of complex IV by E2/ERβ in the heart of male rats that underwent T–H
and that these effects were required for E2-mediated inhibition of
apoptosis induced by T–H. E2/ERα- [357,358] and E2/ERβ-pathways
[359] were involved in protection of myocardial ischemia–reperfu-
sion injury probably via their effects on the preservation and
maintenance of mitochondrial structure and functions [186].
7.5. Implications in beneﬁcial effects of estrogens/ERs on lens physiology
Cataract formation is a multi-factorial eye disease and a leading
cause of blindness worldwide. While surgical procedures correct
vision loss, this presents a substantial ﬁnancial burden on national
health care systems, mandating the search for pharmaceutical agents
that can prevent or delay the onset of cataract. Epidemiological studies
indicate an increased frequency of cataract formation in post-
menopausal women similar to men of the same age in contrast with
a lower incidence in pre-menopausal women, suggesting that the
absence of estrogens in post-menopausal women may contribute to
their increased risk [360]. Several epidemiological studies have
implied that hormone replacement therapy may play some positive
role in delaying or preventing cataract. The Beaver Dam Eye Study
[361] and the Salisbury Eye Study [362] both supported some degree
of protection associated with estrogen and the risk of cataract
development. Aina et al. [363], using a large population based study
of women with reported cataract and age-matched controls, con-
cluded that, “estrogen and estrogen–progesterone hormone replace-
ment therapies are associated with a reduced risk of cataract”.
Work in the Cammarata laboratory has been aimed at elucidating
the biochemical and molecular pathways by which estrogens, which
behave as potent biologically active and selective mitochondrial
protective compounds, may inﬂuence mitochondrial function. But is
there a generally established connection between damaged mito-
chondria and cataractogenesis? “Mitochondriopathies showa chronic,
slowly progressive course and present with multi-organ involvement.
Although several proteins with signaling, assembling, transport and
enzymatic function can be impaired, most frequently the activity of
MRC complexes is primarily affected, leading to impaired oxygen
utilization and reduced energy production [364]”. Among the most
frequently affected systems are eyes and in particular, the lens and the
emergence of cataract. Therefore, cataract is not an exceptional
occurrence in mitochondrial myopathies and should be included
within its multi-system associations [365].
The means by which estrogen and estrogen–progesterone
hormone replacement therapies might restrict or delay the onset
of cataract is unknown. The primary focus of the Cammarata
laboratory has been to demonstrate that E2 protects human lens
epithelial cells against oxidative stress by preserving mitochondrial
function, in part, via the non-genomic rapid activation of prosurvival
signal transduction pathways [59,217,366]. Newly obtained informa-
tion, derived from these recent studies, necessitates a reevaluation of
the past interpretation of the cytoprotective scheme. To that end, this
section of the review will brieﬂy discuss recent data indicating the
coupled duality to E2's cytoprotective action against acute oxidative
stress and offer an interpretation that includes the possibility of
genomic, as well as non-genomic interventions, as inclusive aspects
of the protective mechanism.
E2 administration to the immortalized human lens epithelial cells,
HLE-B3, initiates a rapid increase in intracellular (mitochondrial) ROS.
This, in turn, promptly and transiently increases mitochondrial-
associated MnSOD activity, without alteration in its mRNA expression
or its protein expression proﬁle. The outcome of increasing MnSOD
activity is to immediately lower the mitochondrial ROS concentration
before oxidative damage might ensue [217]. In agreement, estrogen
has previously been reported to increase MnSOD activity levels
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pheochromocytoma cells (PC-12 cells) [367] and MCF-7 breast cancer
cells [54]. Within the same timeframe that estradiol increases MnSOD
activity, estradiol also initiates a signaling cascade culminating in the
activation of the Ras/Raf/ERK (MAPK) and PKA pathways in cultured
HLE-B3 cells [366].
E2 leads to activation (i.e. phosphorylation) of ERK 1/2 (via MAPK)
and Bad (via PKA). Transfection of HLE-B3 cells with ERK2-speciﬁc
siRNA enhanced mitochondrial membrane depolarization subsequent
to peroxide insult whereas Bad siRNA-treated and mock-transfected
cells did not. The implication is that ERK2, but not Bad, plays a pivotal
role in the regulation of mitochondrial membrane potential in human
lens epithelial cells [366]. Estrogen treatment does, however, continue
to offer some protection against mitochondrial membrane depolar-
ization, despite ERK2 suppression. In agreement with this, an earlier
study, using the MEK inhibitor, UO126, also showed that peroxide
insult in the presence of estrogen and UO126 retained a considerable
level of protection against depolarization [368]. That is, if pERK alone
were the sole component driving the protection mechanism, one
might reasonably expect that the loss of mitochondrial membrane
potential be equivalent in the presence of UO126 irrespective of
whether estrogen was present or not. The fact that estrogen retains
the ability to partially prevent depolarization in the absence of ERK
activation suggests at least two parallel protective mechanisms at
play. ERK2, and more speciﬁcally pERK2, represents one pathway of
the estrogen-mediated mitochondrial protection pathway. Alterna-
tively, estrogen may, in part, supersede the necessity for ERK
activation and provide a measure of protection via an ERK-indepen-
dent route [366].
ERβ1 associates with both the nucleus and mitochondriawhile the
ERβ isoform, ERβ2, localizes exclusively with the nucleus [58,59].
ERβ5 is found primarily in the cytosol [58,59]. It has been established
that mitochondrial-associated ERβ1 is a necessary prerequisite for E2-
mediated cytoprotection against H2O2 toxicity as cells transfected
with siRNA-wtERβ1 lost the capability to prevent mitochondrial
depolarization by estrogen intervention [59]. But in the course of
completing these experiments, an interesting fact was uncovered in
that suppression of ERβ1, in turn diminished the relative levels of the
ERβ isoforms, ERβ2 and ERβ5. As such, the working hypothesis was
expanded to include the likelihood that, in conjunction with the non-
genomic rapid activation of prosurvival signal transduction pathways,
estrogen-mediated cytoprotection may include the possibility that
nuclear ERβ2 may provide genomic contribution to the mitochondrial
mechanism of estrogen and estrogen receptors in mitochondrial
protection, possibly via the up-regulation of protective nuclear-
encoded mitochondrial proteins.
Clearly, considerablymorework is needed to fully comprehend the
molecular mechanism(s) of E2 and ERs in mitochondrial protection.
The current conceptual framework regarding the protective mechan-
ism(s) activated by E2 is based on the premise that mitochondrial
cytoprotection will likely prove to be complex and multi-faceted with
contributions from both genomic and non-genomic aspects simulta-
neously providing a combinatorial defense against mitochondrial
permeability transition.
8. Conclusions and prospective
8.1. Conclusions
A proposedmodel that summarizes the effects of E2 and ERs on the
regulation of several aspects of MRC biogenesis and their physiolo-
gical, pathological and pharmacological implications is presented in
Fig. 4. In this fascinating pathway, the transcription factors NRF-1,
NRF-2, PGC-lα and Sp1 play master roles in their regulation of almost
all aspects of MRC protein biogenesis, whereas E2 and ERs serve as the
key “directors” for the entire pathway. This pathway is of physiologicalimportance for the proper functions of a number of cell types and
organs. However, a persistent over-stimulation or deﬁciency of E2/ER-
mediated MRC biogenesis and functions are implicated in the
pathogenesis of a number of diseases in different organs/tissues.
Persistent over-induction of this pathway in breast cells may
contribute to estrogen carcinogenesis and thus, proper inhibition of
this pathway may be valuable for the prevention of breast cancer. In
contrast, the stimulation of this pathway could be highly beneﬁcial in
brain, heart and the eye, whereas a deﬁciency of this pathway in these
organs/tissues could be causally related to the pathogenesis of
neurodegenerative, cardiovascular and the eye diseases.
8.2. Prospective
It should be pointed out that several key aspects of this important
and newly emerging pathway are still far from being understood.
Many new studies are needed to address the following aspects.
8.2.1. Understanding the molecular mechanisms underlying the
E2/ER-mediated coordinate regulation of MRC biogenesis and functions
Several lines of evidence presented above indicate that E2 and ERs
are involved in the coordinate regulation of almost all aspects of MRC
biogenesis, including: 1) nDNA-encoded MRC proteins and MRC
complex assembly proteins; 2) nDNA-encoded protein factors
involved in the replication, transcription and translation of mtDNA;
and 3) nDNA-encoded proteins of mitochondrial protein import
machinery and ANT. What is known, to date, is that E2 and ERs are
involved in the regulation of the proteins involved in these processes
most likely via their stimulation of the expression of several
transcription factors, particularly NRF-1, NRF-2, and Sp1. What is
unknown is whether E2 and ERs simultaneously up-regulate all of the
proteins or whether these factors selectively regulate only speciﬁc sets
of proteins involved MRC biogenesis. In addition, the nature of the
precise molecular mechanisms underlying these effects remains to be
determined. Thus, a comprehensive investigation on the global role of
E2 and ERs on all the aspects of MRC biogenesis, and many detailed
studies on the underlying molecular mechanisms are required. Such
studies will allow a new insight into the role of E2 and ERs in the
regulation of MRC energy metabolism and MRC functions.
8.2.2. Determining whether E2 and ERs are directly involved in the
regulation of MRC complex assembly proteins and the molecular
mechanisms involved
The proper assembly of the nDNA- and mtDNA-encoded MRC
proteins into functionally correct individual MRC complexes relies on
several sets of assembly proteins speciﬁc for the MRC complexes. To
date, little is known about whether the expression and functions of
these assembly proteins are directly regulated by E2 and ERs, though
the binding sites for NRFs have been identiﬁed in the promoters of a
few genes encoding assembly proteins. Because of their crucial role in
MRC biogenesis, the expression of these proteins likely parallels the
E2/ER-induced changes in both nDNA- and mtDNA-encoded protein
subunits. Further investigation on the E2/ER-mediated regulation of
these assembly proteins is essential for a better insight into this
pathway. More importantly, because mutations in assembly proteins
are causally related to a number of lethal mitochondrial diseases (see
Section 2 MRC structure, functions and biogenesis), new knowledge
gained about the regulation of these proteins by E2/ERs will allow the
identiﬁcation of the therapeutic targets for these diseases that can be
treated with E2 and E2-related agents.
8.2.3. Determining how the mitochondrial import of nDNA-encoded
proteins involved in MRC biogenesis is regulated by E2 and ERs
The nDNA-encoded proteins involved in MRC biogenesis are
imported into mitochondria through mitochondrial protein import
machinery. The presence of NRF-1 and NRF-2 binding sites in the
Fig. 4. Proposed Pathway for Regulation of MRC Biogenesis by E2/ERs and Physiological and Pathological Implications. This proposed pathway is simultaneously initiated and
performed within nuclei and mitochondria. Inside the nuclei, the E2-activated ERα and/or ERβ bind to the EREs and other relevant regulatory elements present in the promoter
regions of several key transcription factors including NRF-1, NRF-2 and PGC-lα and activates their transcription. The increased expression of these transcriptional factors, in turn,
stimulate the cooperate expression of nuclear gene encoding: A) a number of proteins factors involved in the replication, transcription and translations of mtDNA; B) the MRC
proteins and MRC complex assembly proteins and C) several proteins of mitochondrial protein import machinery. These proteins are synthesized on cytosolic ribosomes, and
imported into mitochondria via the mitochondrial protein import machinery. The enhanced expression of proteins of mitochondrial import machinery facilitates the mitochondrial
import of proteins involved in the replication–transcription–translations of mtDNA, the nDNA-encoded MRC proteins and MRC complex assembly proteins, along with other
mitochondrially-localized proteins. Within mitochondria, the protein factors involved in mtDNA replication stimulate mtDNA replication and maintain/protection of mtDNA
integrity. On the other hand, ERα and/or ERβ are imported into mitochondria. Once inside the mitochondria, E2 enhances their binding to the mtEREs within the regulatory region
(i.e. D-loop) of mtDNA, to form the active transcription complexes in associationwith the transcriptional factors (e.g. Tfam, TFBIM and TFBIIM) and stimulating mtDNA transcription.
The enhanced levels of protein factors involved in translation ofmitochondrial mRNAs stimulate the translation of thirteenmtRNAs encodingMRC proteins. Both the newly imported,
nDNA-encoded MRC subunits and the newly synthesized, mtDNA-encoded MRC protein subunits are increasingly assembled into individual MRC complexes and ATP synthase by the
increased MRC complex assembly proteins, resulting in increased MRC biogenesis and functions. The consequences of these processes are the increased production of mitochondrial
energy in the form of ATP and MRC-derived ROS. NRF-1, NRF-2, PGC-lα and Sp1 are the master players involved in the regulation of the majority of proteins and important factors
involved in almost all aspects of MRC protein biogenesis. E2 and ERs act as the key “directors” for the entire pathway. The normal operation of this pathway is of physiological
importance for the proper functions of a number of cell types and organs. A persistent over-stimulation or deﬁciency of E2/ER-mediated MRC biogenesis and functions can cause
alterations in mitochondrial functions, resulting in an over-abundance or deﬁciency of ATP and ROS. The changes in ATP and ROS levels and abnormal mitochondrial functions can
also trigger retrograde regulation (e.g. redox-sensitive regulation) of the expression of nuclear genes involved in a wide variety of physiological processes including oxidative
response signaling pathways, various kinase-mediated pathways, cell cycle-related pathways and cell growth/death-related pathways. The combination of these E2/ER-mediated
mitochondrial effects and the resulting retrograde regulation of expression of different types of nuclear genes have a number of physiological implications in different types of cells
and organs. Persistent induction of these mitochondrial effects can exist in breast cells due to relatively higher levels of E2 and ERs in these cells, leading to an over-abundance of
these effects, which may contribute to increased cell proliferation and inhibition of apoptosis as well as resistance to anti-cancer drugs. These effects are relevant to estrogen-
mediated carcinogenesis in human breast. On the other hand, a stimulation of MRC biogenesis/functions by E2 and ERs are highly beneﬁcial for providing the cells in brain, heart and
the eye with sufﬁcient MRC-derived energy for their proper functions. Maintenance of cell survival and inhibition of induced-apoptosis by E2/ER-mediated MRC biogenesis and
functions in neurons in brain, cardiomyocytes in heart and lens cells in the eye confer signiﬁcant protection against AD and PD, heart diseases and the eye diseases (e.g. cataract
formation).
1562 J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1540–1570promoters of the genes for several Tom proteins that are components
of the mitochondrial protein import machinery strongly points to the
possibility that these proteins are regulated by E2 and ERs via NRFs.
However, more work is needed to determine whether E2/ERs are
directly involved in the regulation of mitochondrial protein import
machinery and whether the enhanced expression of these proteins
leads to increased mitochondrial import of proteins required for MRC
biogenesis. To date, at least four different pathways for the sorting andassembly of nuclear-encoded mitochondrial proteins have been
identiﬁed [369]. Thus, one needs to determine which pathway(s)
are employed for the import of these proteins into mitochondria.
Because mutations that disrupt the proper functioning of the
mitochondrial import machinery are related to several diseases
[370], elucidation of how E2 and ERs regulate the import of these
proteinsmay be valuable for ﬁndingways to control themitochondrial
import of these proteins and may lead to development of diagnostic
1563J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1540–1570tools to aid in the identiﬁcation of mitochondrial diseases caused by
defects in the mitochondrial protein import machinery.
8.2.4. Understanding how E2 and ERs regulate the expression of
mtDNA-encoded MRC proteins within mitochondria
A number of studies presented above have demonstrated that the
mitochondrial ERα and ERβ are directly involved in the regulation of
the expression of mtDNA-encodedMRC proteins withinmitochondria.
However, the underlying molecular mechanisms are only partially
understood. Other mitochondrial transcription factors, particularly
Tfam, TFBIM and TFBIIM and several nuclear factors, such as AP-1, Sp1,
p53, NF-B and high mobility group proteins present within mitochon-
dria, might be also involved. Further studies are needed to fully
elucidate the molecular mechanisms by which E2 and ERs in
association with these mentioned proteins regulate the transcription
of mtDNA within mitochondria. In addition, little is known about the
role of E2 and ERs in the regulation of mitochondrial protein
translation andMRC functions. These deﬁcienciesmerit future studies.
8.2.5. Understanding the physiological, pathological and
pharmacological implications of E2/ER-mediated pathway
One of the most important aspects in this area is to delineate the
precise physiological and pathological implications of an over-
stimulation or deﬁciency of this pathway in breast cancer, neurode-
generative and cardiovascular diseases. Further studies are needed to
determine whether an over-stimulation of this pathway in human
breast cells is causally related to the development of breast cancer.
Speciﬁcally, studies are needed to investigate the E2/ER-induced
changes in this pathway during initiation, promotion and progression
of carcinogenesis, invasion, tumoregenesis and metastasis of breast
cancer. Such studies would be valuable for the development of new
intervention approaches to the treatment of breast cancers that would
target this pathway. Further studies to investigate the role of this
pathway in detoxiﬁcation of Tau and β-amyloid toxicity in AD and in
the regulation of the Pink-1–parkin–DJ-1–α-synuclein pathway in AD
could also be valuable and highly beneﬁcial for the development of a
therapeutic treatment for these neurodegenerative diseases that
utilize these target pathways.
Gaining a more complete understanding of E2/ER-mediated path-
ways will lead to new insights into the underlying molecular
mechanisms. Targeting these pathways characterizes a fresh con-
ceptual approach that will contribute to innovative regimens for
prevention or treatment of a wide variety of medical complications.
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